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Zusammenfassung 
Invasive Pilzinfektionen stellen eine ernstzunehmende Bedrohung für immunsupprimierte Patienten 
dar. Die überwiegende Mehrzahl dieser Infektionen wird durch Candida- oder Aspergillus-Arten 
hervorgerufen. Der Hauptverursacher der Invasiven Aspergillose, Aspergillus fumigatus, befällt vor 
allem Stammzelltransplantations- und Organtransplantations-Patienten. Als Risikofaktoren gelten die 
Gabe von Immunsuppressiva sowie hohe Corticosteroid-Dosen. Die Sterblichkeit ist mit 20 bis 80 % 
sehr hoch, was auf unzureichende Wirksamkeit der etablierten Antimykotika zurückzuführen ist. 
Daher ist ein wesentliches Ziel der gegenwärtigen mykologischen Forschung die Identifikation neuer 
therapeutischer Angriffspunkte (drug targets). 
Da die Polysaccharid-Zellwand der Pilze essentiell für die Pilzzelle ist und deren Strukturen in 
menschlichen Zellen nicht vorkommen, stellt deren Biosynthese ein attraktives neues drug target dar. 
Ein Hauptbestandteil der Zellwandkomponenten von A. fumigatus, darunter Glykoproteine, 
Glykolipide und das Polysaccharid Galactomannan, ist der ungewöhnliche Zucker Galactofuranose 
(Galf). Die Glykane menschlicher Zellen enthalten kein Galf, wohl aber Oberflächenmoleküle vieler 
pathogener Mikroorganismen, wie z.B. Mycobacterium tuberculosis oder Leishmania major. Oft sind 
diese Strukturen bedeutsam für die Virulenz oder sogar Lebensfähigkeit dieser Organismen, was eine 
möglicherweise ähnliche Bedeutung von Galf für A. fumigatus nahelegt. 
In dieser Arbeit wurde der Bedeutung der Galactofuranosylierung für A. fumigatus nachgegangen. 
Dazu wurde das UDP-Galf-Biosynthesegen glfA, das für die UDP-Galactopyranose-Mutase (UGM) 
codiert, in A. fumigatus entfernt. In mehreren Experimenten konnte gezeigt werden, dass dieser 
Defekt zu einem vollständigen Verlust von Galf in den Glykanen von A. fumigatus führt. Die ∆glfA-
Mutante ist zudem gekennzeichnet durch einen Wachstumsdefekt und verringerte Sporenbildung, 
geringere Wärmetoleranz und eine erhöhte Sensitivität gegenüber Antimykotika. In 
elektronenmikroskopischen Aufnahmen konnte ein Zellwanddefekt als wahrscheinliche Ursache für 
diesen Phänotyp identifiziert werden. Darüber hinaus erwies sich die ∆glfA-Mutante in einem Maus-
Infektionsmodell der Invasiven Aspergillose als deutlich weniger virulent als der Wildtyp.  
Der zweite Schwerpunkt dieser Arbeit bestand in der Aufklärung weiterer an der 
Galactofuranosylierung beteiligten Proteine von A. fumigatus. In Eukaryonten kann allgemein ein 
UDP-Galf-Transporter für den Transport von UDP-Galf aus dem Cytosol in das ER bzw. den Golgi-
Apparat angenommen werden, allerdings ist eine derartige Aktivität bislang nicht bekannt. Sechzehn 
Gene aus dem Genom von A. fumigatus konnten als mögliche Kandidaten für den UDP-Galf-
Transporter identifiziert werden, von denen eines, glfB, interessanterweise in unmittelbarer Nähe zu 
glfA gefunden wurde. Transport-Experimente zeigten spezifische Bindung von UDP-Galf an GlfB in 
vitro, was auf eine UDP-Galf-Transportaktivität hinwies. Die Bestätigung lieferte eine ∆glfB-
Deletionsmutante, deren Analyse wie schon bei der ∆glfA-Mutante die völlige Abwesenheit von Galf 
ergab. Dieser Befund erlaubte den Schluss, dass die gesamte Galactofuranosylierung in A. fumigatus 
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im ER bzw. Golgi-Apparat stattfindet. Dies gilt insbesondere auch für das Zellwand-Polysaccharid 
Galactomannan, das damit nicht wie andere Zellwand-Polysaccharide an der Plasmamembran 
synthetisiert wird. 
Somit konnte in dieser Arbeit der erste UDP-Galf-Transporter überhaupt identifiziert, sowie dessen 
Bedeutung für die Galactofuranosylierung in A. fumigatus gezeigt werden. Des Weiteren lässt die 
durch den Verlust von Galf verursachte Verminderung der Virulenz von A. fumigatus die UGM als 
mögliches neues drug target in Betracht kommen. 
 
Schlagwörter: Aspergillus fumigatus, Galactofuranose, Virulenz 
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Summary 
Invasive fungal infections pose a serious threat to immunocompromised people. Most of these 
infections are caused by either Candida or Aspergillus species, with A. fumigatus being the 
predominant causative agent of Invasive Aspergillosis. Affected people comprise mainly 
haematopoietic stem cell or solid organ transplant patients who receive either high-dose 
corticosteroids or immunosuppressants. These risk factors predispose to the development of Invasive 
Aspergillosis which is lethal in 20 to 80 % of the cases, largely due to insufficient efficacy of current 
antifungal therapy. Thus one major aim in current mycological research is the identification of new 
drug targets.  
The polysaccharide-based fungal cell wall is both essential to fungi and absent from human cells 
which makes it appear an attractive new target. Notably, many components of the A. fumigatus cell 
wall, including the polysaccharide galactomannan, glycoproteins, and glycolipids, contain the unusual 
sugar galactofuranose (Galf). In contrast to the other cell wall monosaccharides, Galf does not occur 
on human cells but is known as component of cell surface molecules of many pathogenic bacteria and 
protozoa, such as Mycobacterium tuberculosis or Leishmania major. These molecules are often 
essential for virulence or viability of these organisms which suggested a possible role of Galf in the 
pathogenicity of A. fumigatus. 
To address the importance of Galf in A. fumigatus, the key biosynthesis gene glfA, encoding UDP-
galactopyranose mutase (UGM), was deleted. In different experimental approaches it was 
demonstrated that the absence of the glfA gene led to a complete loss of Galf-containing glycans. 
Analysis of the ∆glfA phenotype revealed growth and sporulation defects, reduced thermotolerance 
and an increased susceptibility to antifungal drugs. Electron Microscopy indicated a cell wall defect 
as a likely cause for the observed impairments. Furthermore, the virulence of the ∆glfA mutant was 
found to be severely attenuated in a murine model of Invasive Aspergillosis. 
The second focus of this study was laid on further elucidation of the galactofuranosylation pathway in 
A. fumigatus. In eukaryotes, a UDP-Galf transporter is likely required to transport UDP-Galf from the 
cytosol into the organelles of the secretory pathway, but no such activity had been described. Sixteen 
candidate genes were identified in the A. fumigatus genome of which one, glfB, was found in close 
proximity to the glfA gene. In vitro transport assays revealed specificity of GlfB for UDP-Galf 
suggesting that glfB encoded indeed a UDP-Galf transporter. The influence of glfB on 
galactofuranosylation was determined by a ∆glfB deletion mutant, which closely recapitulated the 
∆glfA phenotype and was likewise found to be completely devoid of Galf. It could be concluded that 
all galactofuranosylation processes in A. fumigatus occur in the secretory pathway, including the 
biosynthesis of the cell wall polysaccharide galactomannan whose subcellular origin was previously 
disputed.    
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Thus in the course of this study the first UDP-Galf specific nucleotide sugar transporter was identified 
and its requirement for galactofuranosylation in A. fumigatus demonstrated. Moreover, it was shown 
that blocking the galactofuranosylation pathway impaired virulence of A. fumigatus which suggests 
the UDP-Galf biosynthesis enzyme UGM as a target for new antifungal drugs.  
 
Keywords: Aspergillus fumigatus, galactofuranose, virulence. 
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Chapter 1 – General Introduction  
1.1 The pathogen Aspergillus fumigatus 
Fungal diseases in healthy individuals comprise harmless superficial infections of skin or mucosa and 
allergic diseases. Immunocompromised people in contrast, might develop invasive fungal infections 
that are lethal if not treated rapidly. Most of these infections are caused by either Aspergillus or 
Candida species with Aspergillus fumigatus being the predominant causative agent of Invasive 
Aspergillosis (IA). This disease affects in particular patients that undergo chemotherapy or 
hematopoietic stem cell transplantation (HSCT) due to haematological malignancies (e.g. leukaemia 
or lymphoma). The incidence of IA in this risk group is currently 2.5-8 % with a mortality of 22-42 % 
(Pagano et al. 2006, Martino et al. 2002, Neofytos et al. 2009). Solid organ transplantation patients are 
the second major risk group. The occurrence of IA depends on the transplanted organ and affects 1-
15 % of transplant patients with a mortality of 55-80 % (Singh and Paterson 2005, Sanchez and 
Larsen 2007). The critical factors predisposing to IA have been identified as neutropenia, i.e. blood 
neutrophil counts < 500 mm-3, and long term therapy with high doses of corticosteroids which impairs 
innate immune cell functions.  
The high mortality makes IA one of the major complications after stem cell or solid organ 
transplantation, it has been estimated to account for 39 % of the nonrelapse mortality (9 % of the 
overall mortality) in HSCT patients (Fukuda et al. 2003). These numbers clearly reflect a deficit in 
effective antifungals.  
Amphotericin B is the classical drug in the therapy of invasive fungal infections. Its binding to 
ergosterol, the principal sterol in the fungal cell membrane, disturbs membrane integrity and 
eventually causes leakage (Odds et al. 2003). Although active against a broad range of fungi, 
amphotericin B is not very selective and thus associated with severe side effects. New lipid 
formulations with less toxicity have been developed, but their high cost opposes routine clinical use.          
The current standard antifungals, the triazoles fluconazole, itraconazole, voriconazole, and 
posaconazole, show improved efficacy and less toxicity (Herbrecht et al. 2002). They act as inhibitors 
of fungal ergosterol biosynthesis. The main drawback is unfavourable interaction with many other 
drugs, including immunosuppressants. Nevertheless the clinical use of voriconazole has considerably 
improved the management of IA  (Zonios and Bennett 2008). The third and newest class of 
antifungals comprises the echinocandins caspofungin, micafungin, and anidulafungin, the two latter 
being approved only for candidiasis. Echinocandins inhibit the biosynthesis of the major cell wall 
polysaccharide, β1,3-glucan, and thus introduce a new drug target in A. fumigatus. Caspofungin is 
currently used as salvage therapy for IA and can be effectively combined with established antifungals 
(Singh et al. 2006, Caillot et al. 2007).    
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1.2 Overview 
1.2.1 Biology of Aspergillus fumigatus 
The natural habitat of Aspergillus fumigatus is the soil. The saprophytic fungus feeds on degradation 
products of organic matter by secreting various hydrolytic enzymes. The A. fumigatus life cycle starts 
with a haploid asexual spore (conidium) that measures 2.5-3 µm in diameter and has a gray-green 
colour due to the presence of melanins in the cell wall. Upon settling on organic substrate that 
provides water, trace elements and sources of carbon and nitrogen the conidium starts swelling (5 h). 
Thereby the outermost layer of the conidial cell wall, a dense hydrophobic protein coat, breaks up and 
exposes the cell wall polysaccharides to the surface. A germ tube eventually emerges from the 
swollen conidium and by constitutive growth at its tip finally forms hyphae. During elongation the 
nuclei divide and hyphae are septated by cell wall-like material yielding separate hyphal cells with a 
single diploid nucleus each. Contact with air induces the formation of conidiophores, i.e. specialized 
hyphal structures that produce conidia (fig. 1-1). Conidiophores consist of a foot cell which terminates 
in a large vesicle covered with a layer of conidia-producing cells (phialides). The conidia form by 
septation of the elongated phialide and remain organized in loosely attached chains. They are easily 
released by air currents and thus ubiquitously found in the environment (Brakhage and Langfelder 
2002). 
  
 
Figure 1-1 Microscopic and macroscopic views of A. fumigatus. Left and right panels, Scanning electron 
micrographs of A. fumigatus conidia, hyphae, and conidiophores at different magnifications (M. Rohde, HZI 
Braunschweig). Middle panel, A. fumigatus culture after three days at 37 °C on minimal medium agar.   
  
A. fumigatus is positioned taxonomically in the pezizomycotina subphylum (formerly euascomycetes) 
of the ascomycota (Hibbett et al. 2007). The pezizomycotina comprise the hyphae-forming 
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ascomycota (‘filamentous fungi’) and harbour most of the species that are pathogenic to humans or 
plants. They can be clearly separated from two other subphyla, the taphrinomycotina and 
saccharomycotina which typically live as unicellular organisms (‘yeasts’, table 1-1). The shared 
characteristic of the ascomycota is the morphologically distinctive ascus, a specialized cell that 
produces sexual ascospores. However, in A. fumigatus, like in many other Aspergilli, sexual 
reproduction is very rare and probably plays a minor role in nature. Indeed, the existence of a sexual 
stage of A. fumigatus was doubted for a long time and was proven only recently (O'Gorman et al. 
2009).     
 
Phylum Species Pathogenic to 
    
Ascomycota  
 ’Yeasts’ (Saccharomycotina, Taphrinomycotina) 
  Saccharomyces cerevisiae Model organism 
  Schizosaccharomyces pombe Model organism 
  Candida albicans Humans 
    
 ’Filamentous fungi’ (Pezizomycotina)  
  Aspergillus fumigatus Humans 
  Penicillium marneffei Humans 
  Neurospora crassa Model organism 
  Histoplasma capsulatum Humans 
  Coccidioides immitis Humans 
  Paracoccidioides brasiliensis Humans 
  Blastomyces dermatitidis Humans 
  
Trichophyton rubrum Humans (Dermatophyte) 
  Botryotinia fuckeliana  Plants 
  Gibberella zeae Plants 
  Magnaporthe grisea Plants 
    
Basidiomycota  
  Ustilago maydis Plants 
  Cryptococcus neoformans Humans 
Table 1-1 Taxonomy of common fungi. Most of the pathogenic fungi 
belong to the subphylum pezizomycotina.  
  
1.2.2 Pathobiology of Aspergillus fumigatus 
Immunity in immunocompetent hosts 
It is estimated that humans typically inhale hundreds of A. fumigatus conidia per day (Latgé 1999). 
Because of their small size these spores reach the lung alveoli, but infection in healthy individuals is 
very rare. Three cellular lines of defence prevent A. fumigatus outgrowth,  tissue-resident alveolar 
macrophages and neutrophil granulocytes as part of the innate immune system and A. fumigatus 
specific TH1 cells as part of the adaptive immunity. 
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In the first line, macrophages phagocytise conidia and secrete pro-inflammatory cytokines 
(importantly TNF-α) and chemokines such as CXCL-2 (Hohl et al. 2005, Steele et al. 2005, Gersuk et 
al. 2006). In the pro-inflammatory cytokine environment, macrophages are stimulated to kill conidia 
in the phagosome by oxidative and non-oxidative mechanisms (Bonnett et al. 2006, Philippe et al. 
2003). Neutrophilic granulocytes leave the bloodstream and migrate to the site of infection in 
response to the chemokines released by alveolar macrophages. They show less phagocytosis capacity, 
but attach to fungal cells and effectively damage conidia and hyphae by releasing antimicrobial agents 
(Diamond et al. 1978, Bonnett et al. 2006); reactive oxygen species play a major role in this process 
(Bonnett et al. 2006). 
The cells of the innate immune system are thought to be most important in preventing Aspergillus 
infection, however, as seen by the susceptibility of AIDS patients to Invasive Aspergillosis, T cells 
are also necessary to provide full resistance. Immature dendritic cells in the lung phagocytise dormant 
conidia, maturate and migrate to the lymph nodes where they prime naive CD4+ T cells to become 
TH1 cells (Langlois and Legge 2007). These cells protect against Aspergillus infection by activating 
macrophages mainly through Interferon-γ and thus increasing their microbicidal potential. The 
protective effect of A. fumigatus-specific TH1 cells could be demonstrated in a mouse model of 
Invasive Aspergillosis (Cenci et al. 2000). Germinated conidia can also be phagocytised by immature 
DCs, however other receptors are involved in binding and uptake. Interestingly, in this case DCs drive 
T cell activation towards TH2 cells. Besides inducing a B cell mediated antibody response, TH2 cells 
deactivate macrophages which worsens the outcome of Aspergillus infection (Langlois and Legge 
2007).    
 
Impaired immunity under immunosuppressive conditions 
Glucocorticoids, e.g. cortisone, decrease the pro-inflammatory capacity of macrophages and 
neutrophils in many ways (Lionakis and Kontoyiannis 2003). The expression of pro-inflammatory 
cytokines and chemokines is downregulated in macrophages and T cells because important signalling 
pathways such as NF-κB, AP-1 and MAPK/ERK are inhibited. As a result the cytokine profile is 
shifted towards a TH2 type which decreases the phagocytosis potential of macrophages and leads to 
insufficient fungal clearance (Lasa 2002, Kamberi 2002, Balloy 2005). Moreover, due to the lack of 
chemokines, the attraction of neutrophils to the site of infection is hindered which further impairs the 
innate immune response. 
Neutropenia or impairment of neutrophil function also predisposes to Invasive Aspergillosis. 
Neutropenia is an unavoidable effect of chemotherapy in the treatment of haematological 
malignancies. Alkylating agents such as cyclophosphamide inhibit cell division of malignant cells but 
also the differentiation of neutrophilic granulocytes which have a short lifetime and thus have to be 
constantly replenished. Chronic Granulomatous Disease is another risk factor for developing Invasive 
Aspergillosis (Antachopoulos et al. 2007). The underlying defect in this disease, a defective NADPH 
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oxidase required to synthesize reactive oxygen species, highlights the importance of oxidative killing 
mechanisms in neutrophil function against A. fumigatus.     
 
Recognition of cell wall carbohydrate motifs by innate immune cells 
The molecular recognition of A. fumigatus by macrophages is only partly understood, but it is clear 
that several receptors exploiting independent signalling pathways are involved. Importantly, conidial 
swelling is a prerequisite for the induction of a cytokine response suggesting that carbohydrate 
structures of the cell wall serve as ligands for macrophage receptors. This has been shown for dectin-
1, a β1,3-glucan receptor which binds to A. fumigatus conidia in the phagosome and contributes to the 
production of TH1 cytokines and chemokines (Hohl et al. 2005, Steele et al. 2005). Toll-like receptor 
2 (TLR2) is also required to ensure full capacity of cytokine production, however its ligand on the 
fungal cell has not been identified (Steele et al. 2005). TLR2 and dectin-1 employ different signalling 
pathways which result in the activation of NF-κB or AP-1 respectively (Toyotome et al. 2008); 
moreover the MAPK/ERK pathway has been shown to be of a certain importance for A. fumigatus 
clearance by alveolar macrophages (Dubourdeau et al. 2006).     
Lung surfactant proteins SP-A and SP-D are lectins that bind A. fumigatus cell wall polysaccharides 
and enhance the phagocytosis and killing capacities of macrophages and neutrophils (Madan et al. 
1997). Dendritic cell receptors for A. fumigatus comprise dectin-1 and DC-SIGN, the latter being 
specific for mannose-containing polysaccharides (Serrano-Gómez et al. 2004).    
 
1.2.3 The A. fumigatus cell wall 
Polysaccharides 
The A. fumigatus cell wall mainly consists of a voluminous polysaccharide network, (glyco)proteins, 
and glycolipids. It serves vital cellular functions, such as mechanical protection and resistance against 
osmotic stress. In transmission electron micrographs the hyphal cell wall appears as a 50 to 330 nm 
bi-layered structure (fig. 1-2) (Reijula 1991, Campbell 1970). The massive electron-lucent inner layer 
contains mostly polysaccharides, while the thin electron-dense outer layer probably represents cell 
wall-associated proteins (Klis et al. 2007). The conidial cell wall has a stronger outer protein layer 
that consists of a dense coat of hydrophobins that prevent desiccation and contains melanin which 
gives conidia their gray-green colour. 
The molecular structure of the A. fumigatus cell wall is relatively well characterized (Fontaine et al. 
2000, Barreto-Bergter et al. 1981). For technical reasons two fractions are commonly distinguished, 
based on their solubility in hot sodium hydroxide: The alkali-soluble fraction (60 % of the cell wall 
mass) containing mostly medium molecular weight polysaccharides and a small amount of protein, 
and the alkali-insoluble fraction (40 %) consisting of a covalent network of high molecular weight 
polysaccharides (fig. 1-3).  
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Figure 1-2 Transmission electron micrographs of A. fumigatus hyphae. A thick electron-lucent layer of 
polysaccharides is covered by a thin electron-dense layer, probably containing proteins. A, 1100x 
magnification; B, 3100x magnification. 
© 2001 Antimicrobial Agents and Chemotherapy, Vol. 45, p. 3310-3321, DOI: 10.1128/AAC.45.12.3310–3321.2001.  
Reproduced with permission from American Society of Microbiology.  
 
The main component (around 45 %) of the alkali-insoluble fraction is β1,3-glucan, i.e. a β1,3-linked 
polymer of glucose. Beta-1,3-glucan is common to all ascomycota and forms the cell wall backbone 
to which the other polysaccharides of the alkali-insoluble fraction are attached. In A. fumigatus 
approximately 4 % of the glucose residues in the β1,3-glucan are substituted at the C6 with small 
β1,3-glucan side chains. These branches provide the anchoring points for chitin (10-20 %), 
galactomannan (14-22 %), and a β1,3/β1,4-glucan (around 10 %). Chitin, a β1,4-N-acetylglucosamine 
polymer, is also a frequent component of fungal cell walls and is thought to confer mechanical 
rigidity. The β1,3/1,4-glucan has not yet been described in any other fungi and its function and 
importance is currently unknown (Fontaine et al. 2000). Galactomannan is a more complex 
polysaccharide and consists of an α1,2- and α1,6-linked mannose core to which several side chains of 
up to five β1,5-linked galactofuranose (Galf) residues are attached. Since Galf does not occur in 
humans, galactomannan is highly immunogenic and assumed to be involved in A. fumigatus 
pathogenicity (Bernard and Latgé 2001). 
The alkali-soluble cell wall fraction contains α1,3-glucan (~ 60 %), free galactomannan (~ 30 %), a 
poly-N-acetylgalactosamine (~ 5 %) and glycoproteins (< 5 %) (Beauvais et al. 2005b, Fontaine et al. 
2000). Due to its missing covalent link to the cell wall backbone this fraction has been described as a 
kind of extracellular matrix (Beauvais et al. 2007). The main constituent α1,3-glucan is a virulence 
factor in other fungi (Histoplasma capsulatum, Cryptococcus neoformans, Paracoccidioides 
brasiliensis, Blastomyces dermatitidis) but not in A. fumigatus (Beauvais et al. 2005b). 
Galactomannan has the same structure and antigenic properties as the cell wall-bound form. Structure 
and function of the minor compound poly-N-acetylgalactosamine are unclear (Fontaine et al. 2000). 
Unlike in yeast, cell wall glycoproteins are not covalently linked to the cell wall but either anchored in 
the plasma membrane or secreted (fig. 1-3).  
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Figure 1-3 Schematic view of the A. fumigatus cell wall constituents. Beta-1,3/1,6-glucan forms a network to 
which chitin, β1,3/1,4-glucan and galactomannan are covalently attached. Alpha-1,3-glucan, soluble 
galactomannan and poly-N-acetylgalactosamine are amorphously distributed in the cell wall. Glycoproteins are 
either secreted or embedded in the plasma membrane. GPI, glycosylphosphatidyl; GIPCs, 
glycoinositolphosphoceramides; Glc, glucose; GlcN, glucosamine; GlcNAc, N-acetylglucosamine; Man, 
mannose; Galf, galactofuranose; GalNAc, N-acetylgalactosamine. 
 
Glycoproteins 
Glycoproteins, either embedded in the plasma membrane or secreted and associated to the cell wall 
polysaccharides, also contribute to the cell wall glycan profile. Asparagine-linked (N-glycans) and 
serine/threonine-linked (O-glycans) glycans are found, but differ from human N- and O-glycans 
(figure 3). Genome comparison with Saccharomyces cerevisiae suggests that the common initiation of 
N-glycan biosynthesis is also preserved in A. fumigatus. Thus, glycoproteins most likely transit from 
ER to Golgi with the consensus Man8GlcNAc2 oligosaccharide. The subsequent processing in the 
Golgi diverges between Aspergillus, yeasts, and humans (fig. 1-4). In Aspergillus niger one or more 
galactofuranose residues are added to the N-glycan core while up to three mannose residues are 
sequentially removed (Takayanagi et al. 1994). In A. fumigatus the core structure might be extended 
by a few mannose residues, before galactofuranose residues are added (Morelle et al. 2005). An often 
found modification specific for yeasts is the addition of up to 150 additional mannose residues to the 
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N-glycan core. However this ‘hypermannosylation’ has not been found in A. fumigatus or any other 
filamentous fungus. 
In contrast to the N-glycan remodelling in fungi, human N-glycans are often transformed into 
complex N-glycans containing little mannose, but instead N-acetylglucosamine, galactose1, fucose 
and sialic acid, all of which are not found in A. fumigatus N-glycans. Notably, galactofuranose is not 
present, neither in yeast nor in human N-glycans.          
 
 
Figure 1-4 Different N-glycan processing in Aspergillus, yeasts and humans. Glycoproteins transit from the ER 
to the Golgi where the ER-derived Man8GlcNAc2 precursor (left) is extensively modified. In Aspergillus, Galf is 
added after partial removal of Man. Yeasts add 50-150 Man residues without removing Man, and in humans 
GlcNAc, Fuc, Gal, and Neu5Ac are sequentially added after Man has been removed. The addition of Galf is 
specific for Aspergillus. Depicted N-glycan structures were suggested for A. fumigatus (Morelle et al. 2005) (top 
left) and A. niger (Takayanagi et al. 1994) (top right). Fuc, fucose; Gal, galactose; Neu5Ac, N-acetyl neuraminic 
acid (sialic acid).  
 
While the N-glycans of A. fumigatus and humans share a common precursor whose structure is partly 
conserved in the mature structures (fig. 1-4), the O-glycans of A. fumigatus and humans are totally 
different. In the fungus, O-glycans are based on a mannose disaccharide to which a chain of up to four 
                                                     
1
 Galactose (Gal) and UDP-galactose (UDP-Gal), whenever used in this text without –f suffix, denote the 
pyranose form of (UDP-)galactose (cf. also 3.2.4). 
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galactofuranose residues is added (fig. 1-3). In turn, human O-glycans contain N-acetylgalactosamine 
(GalNAc), galactose, sialic acid, fucose and xylose, which are absent in A. fumigatus.  
Glycolipids 
A. fumigatus synthesises inositolphosphoceramide (IPC) based glycolipids called GIPCs that have no 
equivalent in human cells. Like in N- and O-glycans and galactomannan, the glycan moiety consists 
of mannose and galactofuranose (Simenel et al. 2008, Toledo et al. 2007). The function of these 
structures is not known, however in the pathogenic fungus Candida albicans transfer of the first 
mannose residue to IPC is required for survival in macrophages and full virulence (Mille et al. 2004).           
Furthermore, A. fumigatus synthesizes glycosylphosphatidylinositol (GPI) anchors. Like in other 
eukaryotes, GPI anchors are fused to the C-terminus of certain proteins and attach them to the plasma 
membrane (fig. 1-3). The A. fumigatus GPI biosynthesis follows the consensus biosynthetic pathway 
of most eukaryotes and is surprisingly not essential for A. fumigatus (Fontaine et al. 2003, Li et al. 
2007). Recently, a galactomannan with a structure identical to the cell wall-bound and soluble form 
was found to be GPI-linked (Costachel et al. 2005). This lipogalactomannan represents a peculiar 
finding, since GPI-based glycoconjugates have been known only from trypanosomatid parasites.      
 
In summary, the glycan structures of A. fumigatus and humans are highly divergent. The complex 
glycans of A. fumigatus are based on a mannose core and are often decorated with one or more 
galactofuranose residues. In contrast, human glycans contain little mannose but N-acetylglucosamine, 
galactose, fucose and sialic acid. These structural differences are based on different biosynthetic 
pathways which provide potential new drug targets given that there is a certain implication of these 
structures in the virulence of A. fumigatus. It is however difficult to predict specific functions for 
certain glycan structures. While cell wall polysaccharides including galactomannan might play a role 
for cell wall stability, the importance of N- and O-glycans depends on the underlying protein for 
whose activity glycosylation might be relevant or not. An intriguing feature of A. fumigatus glycans is 
the frequent occurrence of galactofuranose, because this isoform of galactose is not present in 
humans, but in many other pathogenic microorganisms. 
 
1.2.4 Galactofuranose and its occurrence in microorganisms 
Galactofuranose 
For thermodynamic reasons, 6-carbon aldehyde sugars (aldohexoses) like glucose, galactose or 
mannose appear in nature predominantly as six-membered rings formed by a link between the C5 
hydroxyl group and the C1 carbon atom; this conformation is referred to as the pyranose form.  
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Figure 1-5 The different conformations of galactose. Galactopyranose (Gal) is the most stable and the most 
often encountered conformation in glycan structures while galactofuranose is much rarer. The open chain 
conformation is an unstable intermediate in aqueous solution and does not occur in glycans. The orange 
numbers designate carbon atoms involved in ring formation.   
 
Galactose is exceptionally found to occur in the furanose form, i.e. a five-membered ring through the 
C4 hydroxyl group and C1, designated galactofuranose (Galf) (fig. 1-5). Its prevalence is mainly 
restricted to microorganisms, such as bacteria, protozoa, fungi, and algae but might also be present in 
certain ancient multicellular organisms.    
Already in the 1930’s a polysaccharide containing Galf was isolated from Penicillium charlesii 
(Haworth et al. 1937), later Galf containing glycans were isolated from bacteria (Bourne et al. 1961) 
and parasitic trypanosomatids like Trypanosoma and Leishmania (Turco et al. 1989, de Lederkremer 
et al. 1980).  
 
Galf in bacteria 
Bacterial cell wall glycans often contain sugars that are not present in multicellular organisms, among 
them galactofuranose. A well-known example is the mycobacterial arabinogalactan which connects 
the mycolic acids of the outer mycobacterial cell wall layer covalently to the peptidoglycan through a 
chain of galactofuranose and arabinofuranose. A Mycobacterium smegmatis mutant that is unable to 
synthesize Galf is not viable, probably due to the loss of mycolic acids (Pan et al. 2001). In other 
gram-positive bacteria, Galf occurs for example in teichoic acids of certain serotypes of Streptococcus 
pneumoniae (Beynon et al. 1997), however the precise role of these polymers remains to be clarified.    
Galf is occasionally found in the lipopolysaccharide (LPS) O-antigen of gram-negative bacteria. 
Being the predominant component of the outer membrane, LPS mediates adhesion, evokes immune 
reactions and provides resistance against bacteriophages. The O-antigen part of the molecule consists 
of numerous repeats of an oligosaccharide unit that varies within a species and defines strain-specific 
antigenicity (“O serotypes”). Once in the host, pathogenic bacteria quickly adapt size and composition 
of the LPS O-antigen to escape immune responses, therefore it is recognized as a virulence factor. 
Among the bacterial species that contain Galf in the LPS of certain serotypes are Escherichia coli, 
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Shigella dysenteriae, Klebsiella pneumoniae, Salmonella enterica, and Actinobacillus 
pleuropneumoniae.   
 
Galf in protozoa 
Parasitic protozoa like Trypanosoma cruzi or Leishmania spp. synthesize cell surface glycolipids that 
contain Galf. An important example is the Leishmania lipophosphoglycan (LPG) which consists of a 
phosphodisaccharide repeat unit attached to a Galf containing glycan core. LPG is essential for 
establishment of infection in mammals and thus considered as an important virulence factor of 
Leishmania. Loss of the putative glycosyltransferase required for Galf incorporation into LPG leads to 
the absence of LPG molecules and strongly reduced virulence (Späth et al. 2000). In contrast, the 
terminal Galf residues of  glycoinositolphospholipids (GIPLs) do not contribute to Leishmania major 
pathogenesis, however in Trypanosoma cruzi they are required for adherence to the midgut epithelium 
of the insect vector (Kleczka et al. 2007, Nogueira et al. 2007). 
Similar to A. fumigatus, Galf also occurs as a terminal unit in N- and O-glycans of trypanosomatid 
glycoproteins, however the importance of these modifications has not been investigated yet.    
 
Galf in other organisms 
Although Galf is often regarded as a ‘microbial sugar’ a few reports on Galf in invertebrates and 
plants exist. Glycosides containing Galf have been isolated from flowers and algae (Maksyutina 1967, 
Igarashi et al. 1999) and O-glycans of the alga Chlamydomonas reinhardtii also contain Galf (Bollig 
et al. 2007). The only animal known to produce Galf is starfish (Riccio et al. 1987), besides, genetic 
and biochemical evidence suggests Galf biosynthesis potential also for Caenorhabditis elegans 
(Bakker et al. 2005a, Beverley et al. 2005). Galf has never been found in any vertebrate.    
 
1.3 The Galactofuranosylation Pathway  
The biosynthesis of complex glycans in eukaryotes occurs in the ER and Golgi and follows three 
consecutive steps: i) biosynthesis of nucleotide sugars, i.e. sugars substituted with a nucleoside 
phosphate (UDP, GDP) at the C1, generally in the cytosol; ii) translocation of nucleotide sugars into 
the ER or Golgi lumen by special transport proteins, the nucleotide sugar transporters (NST; see 
below); iii) transfer of sugar residues onto the acceptor by glycosyltransferases.  
The biosynthesis of the nucleotide sugars UDP-Glc, UDP-Gal, UDP-GlcNAc, and GDP-Man is 
conserved between Aspergillus and humans (fig. 1-6). On the level of nucleotide sugar biosynthesis 
only the conversion of UDP-Gal into UDP-Galf is specific for A. fumigatus.  
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Figure 1-6 Glycan biosynthesis pathways in A. fumigatus. Pathway elements are depicted as either specific for 
A. fumigatus (red) or shared with humans (black). Arrows denote enzyme reactions or metabolite transport, 
solid circles represent nucleotide sugar transporters, and solid squares glucan or chitin synthase complexes. 
Human and A. fumigatus enzyme homologs were identified from the KEGG database (www.genome.jp/kegg/). 
 
1.3.1 UDP-galactopyranose mutase 
The enzymatic conversion of UDP-Gal to UDP-Galf was postulated early in fungi (Trejo et al. 1971) 
but the enzyme, UDP-galactopyranose mutase (UGM), was cloned only much later from E. coli 
(Nassau et al. 1996). The reaction follows a unique catalytic mechanism employing an FADH- 
cofactor which facilitates transient ring opening (Soltero-Higgin et al. 2004) (fig. 1-7). The 
mycobacterial UGM is required for arabinogalactan biosynthesis and survival and thus recognized as 
a promising new target in tuberculosis therapy. Recently, inhibitors against mycobacterial UGM 
showed in vitro activity against Mycobacterium smegmatis that was comparable to current 
antimycobacterial drugs (Dykhuizen et al. 2008). The first eukaryotic homologs were identified only 
recently  in A. fumigatus and Leishmania major (Beverley et al. 2005, Bakker et al. 2005a). The 
conservation of the UGM gene allowed identification of homologs in many other eukaryotes, 
including nematodes, algae and tunicates, suggesting a more widespread occurrence of Galf than 
previously thought (Beverley et al. 2005). L. major is however the only eukaryote in which the 
requirement of UGM was studied. Despite absence of a detectable growth phenotype, the L. major 
UGM deletion mutant displayed attenuated virulence in a mouse infection model, probably due to the 
loss of surface lipophosphoglycan (Kleczka et al. 2007).    
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Figure 1-7 Reaction mechanism of UDP-galactopyranose mutase. First an FADH- molecule attacks the C1 of 
UDP-Gal and displaces UDP. A second bond to the C1 opens the ring and yields the depicted galactose-FAD 
intermediate. The ring is closed again by nucleophilic attack of the C4 or C5 hydroxyl group at the C1 resulting 
in either furanose (right) or pyranose (left) formation. Finally, UDP displaces FADH- at the C1 which reforms 
the nucleotide sugar. The reaction is fully reversible and the relative equilibrium amounts are given in 
parentheses.    
 
1.3.2 Galactofuranosyltransferases 
Galactofuranosylation has mainly been studied in bacteria and besides UGM, a few 
galactofuranosyltransferases involved in the biosynthesis of bacterial polysaccharides have been 
characterized. The Mycobacterium tuberculosis enzymes glfT (Rv3808c) and glfT2 (Rv3782) catalyze 
the formation of β1,5- and β1,6-Galf linkages in arabinogalactan (Kremer et al. 2001, Mikušová et al. 
2006) and WbbI (E. coli) and WbbO (Klebsiella pneumoniae) are β-galactofuranosyltransferases 
involved in LPS O-antigen biosynthesis (Wing et al. 2006, Guan et al. 2001). All of them utilize 
UDP-Galf as a donor but no homologs could be found in the genome of A. fumigatus or any other 
eukaryote.  
In contrast to bacteria, only one putative galactofuransoyltransferase of eukaryotic origin has been 
described. The Leishmania protein LPG1 presumably catalyzes the transfer of Galf to the nascent 
LPG chain forming a Galf-β1,3-Man linkage. LPG1 is localized in the Golgi and shows a typical 
glycosyltransferase topology with a short cytoplasmic N-terminus, a single transmembrane domain 
and a large C-terminal part in the Golgi lumen (Ryan et al. 1993, Sean Ha et al. 1996). Homologs 
were identified in other trypanosomatid species but not in any other eukaryote (Zhang et al. 2004).  
 
1.3.3 Nucleotide sugar transporters 
In all eukaryotes studied so far the processing of the N-glycan precursor, O-glycan biosynthesis and 
putatively also GIPC biosynthesis occur in the Golgi. It is thus reasonable to assume that the secretory 
pathway, most likely the Golgi apparatus, is the subcellular compartment of galactofuranosylation in 
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Aspergillus. As UGM is a cytosolic enzyme, a transport mechanism is required to translocate UDP-
Galf from the cytosol into the lumen of the secretory pathway organelle. The negative charge of 
nucleotide sugars prevents passive diffusion through lipid membranes and thus transport is 
accomplished by a special class of transport proteins named nucleotide sugar transporters (NSTs). 
These are very hydrophobic type III transmembrane proteins with 8 or 10 membrane-spanning α-
helices and can be classified into currently six different families (www.tcdb.org) (Jack et al. 2001). 
NSTs show weak primary sequence conservation and little is known on amino acid residues involved 
in substrate binding (Handford et al. 2006). Nevertheless it is still possible to extract candidate NST 
genes from annotated genomes, however in most cases their function cannot be predicted.  
NSTs work as antiporters, i.e. they exchange one nucleotide sugar molecule for one equally charged 
nucleotide which is often the corresponding nucleoside monophosphate (e.g. UDP-Gal/UMP, GDP-
Man/GMP) (Aoki et al. 2003, Segawa et al. 2005). Often NSTs are found to be monospecific with 
little functional redundancy between different NSTs. Consequently, the loss of an NST severely 
impairs glycosylation, as exemplified by the lethal GDP-Man transporter deficiency in several yeasts 
(Dean et al. 1997, Nishikawa et al. 2002a, Nishikawa et al. 2002b). Disease due to NST deficiency is 
also known in humans. For instance, a defective GDP-fucose transporter has been identified to cause 
type II leukocyte adhesion deficiency. This rare inherited disorder is characterized by reduced N-
glycan fucosylation and results in recurrent bacterial infections and severe developmental 
abnormalities (Lübke et al. 2001).         
 
1.4 Objectives 
Bacterial infections can be easily treated with a range of antibiotics since vital cellular functions such 
as protein biosynthesis differ largely from the corresponding processes in human cells. Conversely, 
eukaryotic pathogens, comprising fungi and protozoan parasites, present a particularly challenging 
problem for drug design because of the similarity between the host cell and the pathogen cell. 
Therefore we only dispose of a limited number of drugs for the therapy of fungal and parasitic 
infections. Besides, the available drugs present low to moderate efficacy and are often toxic to human 
cells resulting in severe side effects during therapy.  
Although fungal cells share most of the essential biosynthesis pathways with human cells, a few 
pathways exist that could possibly provide new drug targets. The fungal cell wall is an essential 
feature of fungal cells and consists mainly of glycans that are absent from human cells. Thus the 
corresponding glycan biosynthesis pathways appear as attractive source of new antifungal drugs. 
Indeed, the newest antifungals, the echinocandins, interfere with the synthesis of the main cell wall 
polysaccharide β1,3-glucan and show good efficacy with only mild side effects. 
Galactomannan is the second-most abundant polysaccharide in the A. fumigatus cell wall. It consists 
in roughly equal proportions of mannose and galactofuranose, the latter being entirely absent from 
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human cells. Galf has been known as component of cell surface molecules implicated in virulence or 
even viability of pathogenic microorganisms, such as mycobacterial arabinogalactan or 
lipophosphoglycan of Leishmania major. This suggested that Galf could likewise play a role in 
pathogenicity or viability of A. fumigatus, not least because Galf is also present in A. fumigatus 
glycoproteins and glycolipids.  
To test this hypothesis was the main objective of this study. The recent identification of the UDP-
galactopyranose mutase gene, glfA, in A. fumigatus allowed the generation of a targeted deletion 
mutant (∆glfA) devoid of Galf. Various techniques were employed to prove absence of Galf on the 
surface glycans of the ∆glfA strain. The consequences of the loss of Galf on the in vitro phenotype 
were studied and the virulence of the ∆glfA mutant was assessed in a murine infection model of 
Invasive Aspergillosis.    
Moreover, it was attempted to further define the galactofuranosylation pathway in eukaryotes. Unlike 
bacteria, eukaryotes likely need a UDP-Galf transporter for the biosynthesis of Galf-containing 
glycans. A suitable candidate gene, glfB, was selected from the A. fumigatus genome and its function 
analyzed by in vitro transport assays. The implication of glfB in galactofuranosylation of A. fumigatus 
was determined by analyzing the glycan structures and the phenotype of a ∆glfB deletion mutant.  
The results presented in this study allow to determine the potential of galactofuranose biosynthesis as 
a new antifungal drug target and furthermore help delineating the galactofuranosylation pathway in 
eukaryotes.  
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Chapter 2 – Contribution of Galactofuranose to the 
Virulence of the Opportunistic Pathogen Aspergillus 
fumigatus 
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Preface – About this manuscript 
Prior to this study the glfA gene encoding a homolog of bacterial UDP-galactopyranose mutase 
(UGM) was identified in A. fumigatus by our research group and others (Bakker et al. 2005a, 
Beverley et al. 2005). The following part of my work aimed at generating an A. fumigatus glfA 
deletion mutant (∆glfA) to determine the consequences of the loss of Galf for viability and virulence 
of this fungus. 
For this purpose, two A. fumigatus mutant strains were generated: the ∆glfA strain, in which glfA of 
wild type A. fumigatus was replaced by a bifunctional selection marker, and glfA*, in which the 
selection marker from ∆glfA was replaced again with a modified wild type glfA allele. Subsequently, 
the two mutant strains were analyzed for the presence of Galf by a combination of immunochemical, 
chromatographic and electrophoretic techniques. Several viability parameters were recorded and 
quantified, including growth, sporulation, and thermotolerance. Further analyses included an 
antifungal susceptibility assay and electron microscopy studies of the cell wall. Finally, the virulence 
of the mutant A. fumigatus strains was determined in a experimental mouse infection model and 
correlated to the in vivo growth rate by quantitative PCR. 
My contributions to this manuscript comprised the generation of the two A. fumigatus mutant strains 
∆glfA and glfA*, the characterization of the macroscopic phenotype, the animal studies, and a part of 
the experiments concerning the molecular phenotype. Prof. Routier and I wrote the paper.  
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ABSTRACT 
 
The filamentous fungus Aspergillus fumigatus is responsible for a lethal disease called invasive 
aspergillosis that affects immunocompromised patients. This disease, like other human fungal diseases, is 
generally treated by compounds targeting the primary fungal cell membrane sterol. Recently, glucan 
synthesis inhibitors were added to the limited antifungal arsenal and encouraged the search for novel 
targets in cell wall biosynthesis. Although galactomannan is a major component of the A. fumigatus cell 
wall and extracellular matrix, the biosynthesis and role of galactomannan are currently unknown. By a 
targeted gene deletion approach, we demonstrate that UDP-galactopyranose mutase, a key enzyme of 
galactofuranose metabolism, controls the biosynthesis of galactomannan and galactofuranose containing 
glycoconjugates. The glfA deletion mutant generated in this study is devoid of galactofuranose and 
displays attenuated virulence in a low-dose mouse model of invasive aspergillosis that likely reflects the 
impaired growth of the mutant at mammalian body temperature. Furthermore, the absence of 
galactofuranose results in a thinner cell wall that correlates with an increased susceptibility to several 
antifungal agents. The UDP-galactopyranose mutase thus appears to be an appealing adjunct therapeutic 
target in combination with other drugs against A. fumigatus. Its absence from mammalian cells indeed 
offers a considerable advantage to achieve therapeutic selectivity. 
 
culture (3,9,14). Besides being an abundant 
component of the extracellular matrix, secreted 
galactomannans are used for serological diagnostic of 
invasive aspergillosis (1). The monosaccharide Galf 
has also been reported in the N- and O-glycans of 
some glycoproteins as well as the glycosphingolipids 
of A. fumigatus (47,29,23,41) and represents thus an 
important constituent of this fungus cell wall. Galf is 
otherwise infrequent in natural compounds but 
prevalent in pathogens. Moreover since it is absent 
from higher eukaryotes and involved in the survival 
or virulence of various bacteria, the enzymes involved 
in the biosynthesis of Galf are considered as attractive 
drug targets (32,34).  
Our understanding of Galf metabolism in 
eukaryotes is limited. Galf is most likely incorporated 
into cell surface components by specific 
galactofuranosyltransferases using UDP-Galf
 
as 
donor. The work of Trejo and colleagues in early 
1970s already suggested the existence of an enzyme 
converting UDP-galactopyranose into UDP-galacto-
furanose involved in the biosynthesis of fungal cell 
wall (48). This enzyme named UDP-galactopyranose 
mutase (UGM) and encoded by the glf gene was first 
described in bacteria (17,50,30) and lately in several 
eukaryotic pathogens including A. fumigatus (2,5). 
UGM is to date the only characterised enzyme 
involved in the biosynthesis of galactofuranose 
containing molecules in eukaryotes whereas several 
galactofuranosyl-transferases have been described in 
bacteria (15,19,51,27). The identification of this 
enzyme, highly conserved amongst lower eukaryotes 
and present in many fungi, enables studies on the 
biological role of galactofuranose in these organisms. 
The present report highlights the role of 
galactofuranose in Aspergillus fumigatus growth and 
virulence. 
INTRODUCTION 
 
The filamentous fungus Aspergillus fumigatus is 
the primary cause of invasive aspergillosis, an often 
fatal condition affecting people with a weakened 
immune system. Along with the 
immunocompromised population, the incidence of 
invasive aspergillosis is constantly growing but 
therapy remains problematic. The sterol binding 
polyene amphotericin B and ergosterol biosynthesis 
inhibitor itraconazole have long been the drugs of 
choice for treatment of this infection. But because of 
their higher efficacy and lower toxicity, new triazoles 
such as voriconazole or posaconazole are supplanting 
these drugs  (28,33). 
Additionally, a novel class of antifungal agents 
called the echinocandins provides further options for 
treatment. These compounds inhibit the synthesis of 
β1,3-glucan, a major cell wall component with 
resultant osmotic instability and lysis (12). Their 
minimal toxicity and synergistic activity with 
voriconazole and amphotericin B make them 
particularly attractive for combination therapy 
although clinical validation is still awaited (35,33). 
Despite these advances in therapy, invasive 
aspergillosis is often associated with significant 
morbidity and mortality emphasizing the need for 
novel therapeutic strategies based on the fundamental 
knowledge of A. fumigatus pathogenesis.  
The development of echinocandins illustrates the 
viability of targeting enzymes involved in cell wall 
biosynthesis and encourages the development of 
chitin synthesis inhibitors. Like glucan and chitin, 
galactomannan is an abundant component of A. 
fumigatus cell wall (4). This polysaccharide 
composed of a linear mannan core branched with 
short β1,5-linked galactofuranose (Galf) chains (22) 
is covalently bound to the cell wall β1,3-glucan, 
anchored to the lipid membrane by a 
glycosylphosphatidylinositol (GPI), or released in the 
environment during tissue invasion or growth in 
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Table 1. DNA oligonucleotides used in this study. 
Oligonucleotide  Sequence (5’->3’; restriction site underlined) Description (Restriction site) 
PS1 
PS12 
PS3 
PS4 
PS66A 
PS67A 
PS68A 
PS69A 
PS20 
PS21 
PS23s 
PS23r 
PS28 
PS31 
PS78 
PS79 
Probe 
ATAAGCGGCCGCAAGCTGGGAACGCGATTCAA 
TATACCGCGGCTGCCAAGCTATCAGTTTCC 
ATCCGGTGCTCAGGTATTCGCCA 
ATCCATCGATCATATCCTATGCGGTCTCAG 
TTACGCATTCCCAGCAGTTG 
TGCGCTGTGATGAATGGTGT 
TCCACAATACGTCCCCTACA 
GTATGAACCCTCTCCCAATG 
AAGGTCGTTGCGTCAGTCCA 
TCGATGTGTCTGTCCTCC 
ATGCCGCTCTCGAGGCTCGT 
CACGAGCCTCGAGAGCGGCA 
ATATGCGGCCGCAAACAGGAGCGAAGTAGT 
ATATCCCGGGAGTTTGGTGCTGTGGTAGGT 
CGTGTCTATCGTACCTTGTTGCTT 
AACTCAGACTGCATACTTTCAGAACAG 
FAM-CCCGCCGAAGACCCCAACATG-TAMRAa 
5’ flanking region p∆glfA reverse (NotI) 
5’ flanking region p∆glfA sense (SacII) 
3’ flanking region p∆glfA sense (EcoRV) 
3’ flanking region p∆glfA reverse (ClaI) 
Southern Blot probe 1 sense 
Southern Blot probe 1 reverse 
Southern Blot probe 2 sense 
Southern Blot probe 2 reverse 
Southern Blot probe 3 sense 
Southern Blot probe 3 reverse 
Site-directed mutagenesis glfA* sense (XhoI) 
Site-directed mutagenesis glfA* reverse (XhoI) 
5’ flanking region pglfA* sense (NotI) 
3’ flanking region pglfA* reverse (XmaI) 
18S rRNA gene fragment sense 
18S rRNA gene fragment reverse 
qPCR hybridization probe 
 aFAM, carboxyfluorescein; TAMRA, carboxytetramethylrhodamine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIAL AND METHODS 
 
Strains, media and growth conditions. 
 Aspergillus fumigatus clinical isolate D141 (38) was 
used as wild type strain in this study. All strains were 
grown at 37 °C on Aspergillus minimal medium 
(AMM) containing 1 % D-glucose as carbon source 
and 70 mM NaNO3 as nitrogen source (36) unless 
otherwise stated. Phleomycin or 5-fluoro-2’-
deoxyuridine (FUDR) were added for selection 
purposes at 30 µg/mL and 100 µM respectively.  
 
Generation of A. fumigatus mutant strains. The 
5’ and 3’ flanking regions (1.5 and 2 kb respectively) 
of A. fumigatus glfA coding sequence were amplified 
from genomic DNA by PCR with primers PS12/PS1 
and PS3/PS4 (Table 1) respectively and cloned into 
the pBluescript II  
SK(-) vector (Stratagene) using the restriction sites 
SacII/NotI and EcoRV/ClaI. A SpeI/NotI fragment 
released from pSK269 containing the phleo/tk blaster 
(18) was then inserted between the two fragments to 
obtain the disruption plasmid p∆glfA. For 
reconstitution of the glfA gene locus, the plasmid 
pglfA* was constructed as follows. The phleo/tk 
blaster of p∆glfA was first replaced with the original 
A. fumigatus glfA gene by homologous 
recombination in E. coli strain YZ2000 (Gene 
Bridges, Leimen, Germany). A single point mutation 
was introduced by site-directed mutagenesis. Briefly, 
non-methylated plasmid DNA was generated from a 
methylated parent plasmid by Phusion DNA-
Polymerase (NEB) using complementary primers that 
both carried the desired mutation (PS23s/PS23r, Table 
1). Prior to transformation the parental, methylated 
DNA strand was specifically cleaved by DpnI to 
selectively obtain transformants that harbored the 
mutated plasmid. Thus, codon 130 of glfA coding 
sequence (GenBank Accession number AJ871145) 
was changed from CTT to CTC which generated a 
new XhoI restriction site. Since gene reconstitution by 
homologous recombination could not be obtained 
with this construct, 5’ and 3’ flanking regions were 
extended to 5 kb by replacement with re-cloned PCR 
fragments (primer pairs PS28/PS1 and PS3/PS31) to 
obtain the final pglfA* construct.  
The p∆glfA and pglfA* plasmids were linearised 
(KpnI/SacII) before polyethylene glycol-mediated 
fusion of protoplasts as described in (37). 
Transformants were grown on AMM plates 
containing 1.2 M sorbitol as osmotic stabiliser under 
appropriate selection conditions and singled out twice 
before further analysis. Accurate gene deletion and 
reconstitution were confirmed by southern 
hybridisation. Southern probes were amplified from 
genomic DNA using primer pairs PS66A/PS67A, 
PS68A/PS69A and PS20/PS21. All primer sequences 
are provided in Table 1. 
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Western Blots. Cell wall glycoproteins and 
soluble polysaccharides were extracted from 30 mg 
ground A. fumigatus mycelium by incubation in 1 
mL sample buffer (15 % glycerol, 100 mM Tris/HCl 
pH 6.8, 1.5 % SDS, 0.25 % β-mercaptoethanol, 0.025 
% bromophenol blue) for 12 min at 95 °C. 20 µl of 
the supernatant were separated on a 10 % SDS-
polyacrylamide gel and transferred to nitrocellulose 
membranes. The monoclonal antibody EB-A2 (42) 
conjugated to horseradish peroxidase (HRP) from the 
Platelia Aspergillus Test (Bio-Rad, Hercules, CA, 
USA) or HRP-coupled lectin Concanavalin A (ConA, 
Sigma-Aldrich) were used in a 1:50 dilution or at 0.2 
µg/mL respectively. HRP activity was visualised by 
an enhanced chemiluminescence system (Pierce, 
Rockford, IL, USA). 
 
N-glycan analysis. N-glycans of secreted 
glycoproteins in the supernatant of an A. fumigatus 
liquid culture were analyzed after Peptide N-
Glycosidase F (PNGase F) mediated release and 8-
amino-1,3,6-pyrenetrisulfonic acid (APTS) labeling 
by capillary electrophoresis as recently described 
(20). Separation was carried out on a 4-capillary 
electrophoresis DNA Sequencer (3130 Genetic 
Analyzer, Applied Biosystems, Foster City, CA, 
USA). Oligomaltose and bovine RNAse B N-glycans 
(Prozyme, San Leandro, CA, USA) served as 
reference oligosaccharides. 
 
Purification and analyis of glycosylinositol-
phosphoceramides (GIPCs). Mycelia (0.5 g) ground 
in liquid nitrogen with a mortar and pestle were 
disrupted by sonication in 6 mL of CHCl3/MeOH 1:1. 
After addition of 3 mL CHCl3 (to obtain a 
CHCl3/MeOH ratio of 2:1), GIPCs were extracted at 
room temperature for at least 15 min on a rotating 
shaker. 3 mL MeOH were then added to lower the 
density and the mixture centrifuged for 10 min at 
2000 g to remove insoluble material. Chloroform and 
H2O were then added to the supernatant to obtain a 
biphasic system with an 8/4/3 ratio of 
CHCl3/MeOH/H2O. After centrifugation for 10 min at 
2000 g, GIPCs contained in the upper phase were 
collected and applied to a C18/SepPak cartridge 
(Waters, Eschborn, Germany) pre-equilibrated with 
5 mL CHCl3/MeOH/H2O 3/48/47. After washing of 
the column with 20 mL CHCl3/MeOH/H2O 3/48/47, 
glycolipids were eluted with 5 mL methanol and 
dried under a stream of nitrogen. High performance 
thin layer chromatography and immunostaining with 
the monoclonal antibody MEST-1 were carried out as 
previously described (47). 
  
Growth assay. For radial growth measurement, a 
10 µl drop containing 10,000 A. fumigatus conidia 
was placed in the centre of an agar plate containing 
either minimal (AMM) or complete medium (potato 
dextrose agar, Becton Dickinson Difco, Heidelberg, 
Germany). Plates were incubated at various 
temperatures and colony diameters were measured 
twice daily.  
 
Antifungal susceptibility testing. The reference 
broth microdilution test was applied for A. fumigatus
antifungal susceptibility testing (21). Each antifungal 
stock was diluted in 200 µl double-strength RPMI 
2%G (RPMI 1640 liquid medium buffered with 
165 mM 4-Morpholinepropane-sulfonic acid (MOPS) 
to pH 7.0 and supplemented with 2 % glucose) to 
obtain the highest concentration to be tested. Nine 
serial 1:2 dilutions in double-strength RPMI 2%G 
were made and to each dilution an equal volume 
(100 µl) of an A. fumigatus spore solution (2.5·105/mL 
in water) was added. Microtitre plates were incubated 
at 35 °C and fungal growth in each well was read out 
visually after three days and compared to control wells 
that contained no antifungal.  
 
Field emission scanning electron microscopy. For 
morphological studies and measurements of the cell 
wall thickness A. fumigatus wild type and ∆glfA
mutant mycelium were fixed in 5 % formaldehyde and 
2 % glutaraldehyde in cacodylate buffer (0.1 M 
cacodylate, 0.01 M CaCl2, 0.01 M MgCl2, 0.09 M 
sucrose, pH 6.9) for 1 h on ice. Samples were washed 
several times with cacodylate buffer and subsequently 
with TE-buffer (20 mM Tris/HCl, 1 mM EDTA, pH 
6,9) before dehydration in a graded series of acetone 
(10, 30, 50, 70, 90, 100 %) on ice for 15 min per step. 
Samples in the 100 % acetone step were allowed to 
reach room temperature before another change in 100 
% acetone. Samples were then subjected to critical-
point drying with liquid CO2 (CPD 30, Balzers, 
Liechtenstein). Dried samples were then mounted onto 
conductive carbon adhesive tabs on an aluminium stub 
and sputter coated with a thin gold film (SCD 40, 
Balzers Union, Liechtenstein). For cell wall thickness 
measurements mycelium was fractured by pressing 
another conductive carbon adhesive tab covered stub 
onto the sample and separating both stubs 
immediately thereafter. Fractured hyphae were also 
made conductive by sputter coating with a gold film 
before examination in a field emission scanning 
electron microscope (Zeiss DSM 982 Gemini) using 
the Everhart Thornley SE-detector and the inlens SE-
detector in a 50:50 ratio at an acceleration voltage of 5 
kV and at calibrated magnifications. 
 
Mouse infection model. A low-dose mouse 
infection model of Invasive Aspergillosis for Balb/c 
mice which had been established previously (25) was 
essentially used. Immunosuppressive state was 
established by intraperitoneal injections of 100 mg/kg 
cyclophosphamide (Endoxan, Baxter Chemicals) on 
days -4, -1, 0, 2, 5, 8 and 11 and a single subcutaneous 
dose (200 mg/kg) of a cortisone acetate suspension 
(Sigma) on day -1. Groups of 20 mice were infected 
intranasally with 20,000 conidia of wt, ∆glfA or glfA* 
strain on day 0. The control group received PBS only. 
Survival was monitored for 13 days after infection and 
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moribund animals were sacrificed. Coincidence of 
severely reduced mobility, low body temperature and 
breathing problems was defined as moribundity 
criterion. Statistical analysis of survival data was 
carried out using the logrank test implemented in 
Prism 4 (GraphPad Software, San Diego, CA, USA). 
For quantification experiments, groups of three to 
five animals were killed two, four and six days after 
infection and lungs were removed for further 
analysis.  
 
Lung histology. Female Balb/c mice were 
immunosuppressed and infected as described above. 
The animals were killed after 5 days and their lungs 
removed and fixed in 4 % PBS-buffered 
paraformaldehyde over night. Tissue samples were 
dehydrated through a series of graded alcohols, 
cleared with xylene and embedded in paraffin. Tissue 
sections (5 µm) were stained with either 
hematoxylin/eosin or by the Periodic Acid Schiff 
(PAS) method for visualization of fungal cell walls. 
Photomicrographs were taken with an Axiovert 
200 M microscope (Zeiss, Germany) at 10x and 20x 
magnification.  
 
Preparation of genomic DNA from mouse lungs. 
Tissue homogenisation was modified according to 
(7). Immediately after removal, mouse lungs were 
transferred to a 2 mL screw-cap containing 1.4 mm 
ceramic beads (Lysing matrix D, Qbiogene, Irvine, 
CA, USA) and 20 % glycerol/PBS. Tissue was 
disrupted using a FastPrep FP120 instrument 
(Qbiogene) for 3 times 30 seconds at speed 5 with 
intermediate cooling on ice. The disrupted tissues 
were further homogenised with approx. 250 mg acid-
washed glass beads (0.45-0.5 mm, Sigma-Aldrich) by 
vortexing three times for 30 s with intermediate 
cooling on ice. The DNeasy Blood & Tissue Kit 
(Qiagen, Hilden, Germany) was used to extract 
genomic DNA from an equivalent of 8 % of the 
starting tissue material of this homogenate. DNA was 
finally recovered in 200 µl elution buffer. 
 
Quantitative PCR (qPCR). Quantitative PCR was 
carried out essentially as described previously (7). 
Primers for amplification of a 18S rRNA gene 
(GenBank Accession number AB008401) fragment 
specific for A. fumigatus and a hybridisation probe 
labeled with carboxyfluorescein (FAM; 5’ end) and 
carboxytetramethylrhodamine (TAMRA; 3’ end) 
were designed using Primer Express software version 
3.0 (Applied Biosystems; Table 1). qPCR reactions 
were performed in a 7500 Fast Real-Time PCR 
System instrument (Applied Biosystems) loaded with 
MicroAmp optical 96-well plates sealed with Optical 
Adhesive Cover (Applied Biosystems). Each qPCR 
reaction (20 µl) contained 5 µl sample DNA, 250 nM 
dual-labeled hybridisation probe, 500 nM primers, 
250 µg/mL BSA and TaqMan Fast Universal Master 
Mix (Applied Biosystems) containing dNTPs, buffer 
and the fluorescent dye carboxyrhodamine (ROX) as 
a passive reference. Real-time PCR data was acquired 
using Sequence Detection Software v1.3.1. 
FAM/ROX fluorescence ratio was recorded at every 
cycle and a CT value was assigned to each reaction, 
defining the cycle number at which the FAM/ROX 
signal surpassed an automatically defined threshold. 
CT values were corrected for differences in yield of 
genomic DNA by normalization to DNA 
concentration of a control sample using the formula 
CT,norm = CT,measured + log2([DNA]sample / [DNA]control) 
(7). Translation of sample CT,norm values into rDNA 
gene copy numbers was done as follows: CT values of 
serial 1:10 dilutions containing N = 300 to 300,000 
molecules (calculated from Mw and DNA 
concentration determined by OD260) of a plasmid 
bearing the cloned A. fumigatus 18S rDNA gene were 
plotted against N to generate a calibration curve which 
was then used to assign a rDNA copy number to a 
given sample CT,norm value. Conidial equivalents were 
calculated from gene copy numbers by means of 
uninfected tissue samples that were spiked with 
defined numbers of conidia before tissue 
homogenisation (7). Samples, controls and standards 
were analyzed in triplicates. 
 
 
RESULTS 
 
Deletion and reconstitution of the glfA gene in A. 
fumigatus. To begin investigating the role of Galf in 
Aspergillus fumigatus biology, we deleted the gene 
encoding UGM (GenBank locus tag AJ871145) and 
named it glfA following the recommendations for gene 
naming in Aspergillus. To do this, we generated a 
deletion plasmid containing the regions flanking the 
glfA coding sequence separated by the bifunctional 
selection cassette phleo/tk that confers both resistance 
to phleomycin and sensitivity to 5-fluoro-2’-
deoxyuridine (FUDR) (18). This construct was used to 
transform protoplasts of A. fumigatus clinical strain 
D141 which served as wild type (wt) and phleomycin 
resistant transformants were analyzed by Southern 
Blot using several digoxigenin-labeled probes (Fig. 1). 
One of the clones that had undergone the desired gene 
replacement (Fig. 1) was selected for further analysis 
and named ∆glfA. 
The selected disruptant was further subjected to 
protoplast transformation with a large DNA fragment 
encompassing the glfA coding sequence which 
contained a single translationally silent nucleotide 
exchange that generated an XhoI restriction site. Gene 
replacement in the transformants resulted in the 
reconstitution of the glfA locus (Fig. 1) as detected by 
FUDR resistance and proven by Southern Blot 
analysis for a selected clone named glfA* (Fig. 1B). 
The silent mutation introduced in the reconstituted 
strain allowed differentiating between wild type and 
glfA* as demonstrated in figure 1B (top) and thus 
enabled us to rule out contamination by the wt strain. 
The reconstitution of the glfA locus ensures that any 
phenotype observed in the ∆glfA strain can be reverted 
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and hence be securely attributed to the loss of the glfA 
gene.  
 
Galf is absent from the A. fumigatus ∆glfA 
mutant. To confirm that deletion of glfA indeed 
altered the expression of Galf containing 
glycoconjugates, aqueous mycelial extracts were 
tested for reactivity to the Galf-specific monoclonal 
antibody (mAb) EB-A2. This antibody recognizes 
preferably β1,5-linked Galf-residues that are present 
in all forms of galactomannan (cell-wall bound, 
membrane bound or secreted) (42) as well as in some 
O-glycans (23). Moreover a second binding epitope, 
Galf(β1,2)Man, which is part of galactofuranosylated 
N-glycans has been postulated (29). Thus, EB-A2 can 
be used to simultaneously detect galactomannan and 
galactofuranosylated glycoproteins. Western blot 
analysis of wt and glfA* total mycelial extracts labeled 
with horseradish peroxidase (HRP) conjugated EB-A2 
revealed a smear migrating around 40 to 80 kDa in 
accordance with previous findings (42). In contrast, 
the ∆glfA mycelial extract was not stained at all, 
indicating absence of Galf in the galactomannan and 
glycoproteins of this mutant (Fig. 2A, left). In 
contrast, Concanavalin A (ConA) used as loading 
control bound slightly better to the ∆glfA extract than 
to those of wt and glfA* (Fig. 2A, right). The lack of 
Galf in the ∆glfA mutant might increase the 
accessibility of the mannan for ConA and thus could 
explain this finding.  
Similarly, the absence of Galf in ∆glfA glycolipids 
was shown by the absence of reactivity to the 
monoclonal antibody MEST-1. This antibody that 
recognizes β1,3- and β1,6-linked Galf residues (43) 
Figure 1 A) Schematic representation of the chromosomal glfA locus in wild type, ∆glfA and reconstituted wild type glfA*. Thick black 
bars show flanking regions used for homologous recombination. The positions of probes (1-3) used for Southern Blot along with respective 
restriction fragments (size in kb) are indicated. B) Southern Blots of genomic DNA digested with indicated restriction enzymes and 
hybridised to different digoxigenin-labeled probes. wt, wild type; ble/tk, phleomycin resistance/thymidine kinase fusion gene; P, promoter; 
T, terminator.  
 
Figure 2 A) Western Blots of A. fumigatus mycelial extracts containing glycoproteins and cell wall polysaccharides stained with 
horseradish peroxidase conjugates of either Galf-specific mAb EB-A2 (left) or α-mannose binding lectin Concanavalin A (right). B) A. 
fumigatus GIPCs separated by High Performance Thin Layer Chromatography and stained with Galf-specific mAb MEST-1 (left) or orcinol 
(right). White bars indicate the origin. 
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Figure 3 A) Electropherograms of fluorescently labeled N-glycans enzymatically released from secreted A. fumigatus glycoproteins. 
Oligosaccharides from wt and ∆glfA were either untreated (panels 1 and 2), digested with T. reesei α1,2-exomannosidase with or without 
hydrofluoric acid treatment (panels 3 to 6) or digested with Jack Bean α-mannosidase (panels 7 and 8). Bovine RNAse B N-glycans served 
as reference (panel 9). B) Structures of bovine RNAse B reference N-glycans. C) Major N-glycans found on A. niger α-galactosidase and α-
glucosidase (44,45). Black squares, N-acetylglucosamine; grey circles, mannose; white pentagon, galactofuranose.  
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Figure 4 A) Colony morphology of A. fumigatus on minimal agar after two days. White bars represent 1 cm. B) Absolute and relative 
(compared to wild type) growth rates derived from three independent experiments. P value from a t test indicates statistical significance 
(***, P < 0.001; ns, not significant). 
 
labeled several A. fumigatus 
glycosylinositolphosphoceramides (GIPCs) after 
separation by high-performance thin layer 
chromatography as previously shown (47) but did not 
label glycosphingolipids extracted from the ∆glfA 
mutant (Fig. 2B, left). The upper bands observed in 
this panel might be attributed to GIPCs containing 1 
or 2 Galf and 2 or 3 mannose residues as recently 
described (41,47). In addition, Simenel et al. reported 
an unusual GIPC containing a Galf residue 
substituted by a choline phosphate. The lower band 
present in the wt chromatogram could correspond to a 
similar GIPC. Staining of glycolipids by orcinol was 
used as loading control (Fig. 2B, right). The simpler 
∆glfA chromatogram is compatible with the absence 
of Galf containing GIPCs. The uppermost band 
observed in the chromatogram most probably 
correspond to Man(α1,3)Man(α1,2)Ins-P-Cer while 
the band just beneath could be attributed to 
Man(α1,2)Man(α1,3)Man(α1,2)Ins-P-Cer (47). The 
chromatograms obtained from the reconstituted 
mutant glfA* and wt were undistinguishable (data not 
shown).  
Additionally, N-glycans enzymatically released 
from A. fumigatus secreted proteins were analyzed by 
capillary electrophoresis after fluorescent labeling 
(20,8). The profiles obtained are presented in figure 
3A (panels 1 and 2). The peaks labeled 1, 2, 3, 4 and 
5 present in both electropherograms co-migrated with 
reference oligosaccharides M5 to M9 (Fig. 3A; panel 
9 and Fig. 3B). Moreover, digestion of these N-
glycans by Trichoderma reesei α1,2-mannosidase 
indicates that 2, 3, 4 and 5 arise from substitution of 
oligosaccharide 1 with one to four mannose residues 
linked in α1,2 (Fig. 3A; panels 3 and 4). The profile 
obtained with wt N-glycans (Fig. 3A; panel 1) 
presents four additional peaks labeled 1a, 2a, 3a and 
4a that were absent from glfA N-glycans. The 
retention times of these peaks suggest that they arise 
from substitution of oligosaccharides 1-4 with a single 
Galf residue. The presence of a terminal non-reducing 
Galf residue in A. fumigatus N-glycans has been 
previously reported (9) and was demonstrated by 
hydrofluoric acid (HF) treatment of the N-glycans 
after Trichoderma reesei α1,2-mannosidase digestion 
(Fig. 3A, panels 5 and 6). This mild acid treatment, 
known to release Galf, entirely converted 
oligosaccharide 1a into oligosaccharide 1 (Fig. 3A; 
panels 3 and 5). In contrast, HF treatment did not 
change the profile of ∆glfA N-glycans digested with 
α1,2 mannosidase (Fig. 3A, panels 4 and 6).  
Interestingly, the comparison of wt and ∆glfA N-
glycans digested with T. reesei α1,2 mannosidase or 
Jack Bean mannosidase helps positioning the Galf
residue. Alpha1,2-mannosidase treatment converted 
the oligosaccharides 2a, 3a and 4a into 1a while the 
oligosaccharides 2, 3 and 4 generated 1 (Fig. 3A; 
compare panels 1 and 2 with 3 and 4). This indicates 
that the Galf residue does not protect any mannose 
residues from the exomannosidase digestion and thus 
does not substitute an α1,2-linked mannose (Fig. 3A; 
panels 3 and 4). Moreover, Jack Bean mannosidase 
digestion of wt N-glycans resulted in a major peak 
(peak 7), attributed to GalfMan3GlcNAc2 from its 
retention time, in addition to Man1GlcNAc2 (peak 6) 
expected from digestion of high-mannose type N-
glycans (Fig. 3A; panels 7 and 8). These experiments 
do not allow for the determination of  the detailed N-
glycan structure but suggest that they resemble the N-
glycans of A. niger α-glucosidase and α-galactosidase 
(44,45). More importantly, these experiments 
demonstrate the absence of Galf in the ∆glfA N-
glycans. 
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Table 2. MICs of various antifungal agents against A. fumigatus 
mutants obtained from a broth microdilution assay. 
 
Genotype AmBa Vorb Casc NiZd H2O2e 
mg/L 
Wt 3.9 0.3 62.5 500 218 
∆glfA 2.0 0.04 31.3 62.5-125 218 
glfA* 3.9 0.3 62.5 500 218 
aAmphotericin B (MIC90), bVoriconazole (MIC50), 
cCaspofungin (MIC90), dNikkomycin Z (MIC50), 
eMIC100.
Figure 5 Field emission scanning electron micrographs of cross-fractured mycelial walls of A. fumigatus wt and ∆glfA. Panel 1 and 3 
display the highest measurement of cell wall thickness. Panel 2 and 4 present two measurements illustrating the 50% reduction of ∆glfA cell 
wall thickness. 
 
Loss of Galf
 
alters morphology and growth of A. 
fumigatus. The ∆glfA strain exhibited a marked 
growth defect on solid minimal media or complete 
media when compared to wt. This effect could be 
observed for a wide range of temperatures (Fig. 4) 
and was statistically different in all cases (P < 0.001, t 
test, n = 3). The most severe effect was found at 42 
°C with a 75 % reduction in radial growth (Fig. 4C). 
In parallel, ∆glfA conidiation was diminished by 90 
% at 37 °C and was almost absent at 42 °C. In 
contrast, the onset and rate of germination of wt, 
∆glfA and glfA* conidia were similar. In minimal 
media at 37 °C, the conidia of all strains started 
forming germ tubes at 3.2 h and reached 100 % 
germination within 8 to 9 h (data not shown).  
Scanning electron micrographs of intact mycelium, 
conidiophores and conidia of ∆glfA did not reveal any 
obvious morphologic differences. However, the 
observation of fractured mycelium revealed a marked 
reduction of the ∆glfA cell wall thickness (Fig. 5). 
Measurements indicated that the cell wall of wt A. 
fumigatus varies from 85 to 315 nm which is in good 
agreement with earlier findings (39). In contrast, 
∆glfA cell wall thickness ranged from 85 to 150 nm. 
The mean values (± standard deviation) of cell wall 
thickness obtained from 25 measurements were 227.5 
nm (± 15.98 nm) and 109.7 nm (± 11.3 nm) for wt 
and ∆glfA hyphae respectively. The cell wall of ∆glfA 
was thus approximately half the thickness of the wild 
type cell wall. 
 
∆glfA is more susceptible to drugs. The structural 
cell wall defect caused by Galf deficiency was 
accompanied by an increased susceptibility to several 
antifungal agents (Table 2). MICs determined in a 
broth microdilution test were slightly reduced for 
amphotericin B and caspofungin in the ∆glfA mutant. 
A more pronounced increase in susceptibility was 
seen for voriconazole (0.04 mg/L for ∆glfA compared 
to 0.3 mg/L for wt) and nikkomycin Z (63-125 mg/L 
for ∆glfA and 500 mg/mL for wt), suggesting an 
increased permeability of the cell wall caused by the 
loss of Galf. In contrast, the sensitivity towards 
oxidative stress remained unchanged as indicated by 
equal MICs for H2O2 in both wt and ∆glfA. 
 
∆glfA displays attenuated virulence in a murine 
model of invasive aspergillosis. The influence of the 
glfA deletion on pathogenicity of A. fumigatus was 
assessed in a low-dose infection model of invasive 
aspergillosis (25). Cyclophosphamide was used to 
induce neutropenia in female Balb/c mice and a single 
dose of cortisone acetate was administered before 
intranasal infection with 20,000 A. fumigatus conidia. 
Neutropenia was maintained throughout the 
observation period of 13 days and survival was 
recorded daily (Fig. 6A). 90 % of the animals infected 
with wt did not survive day seven after infection, 
whereas half of the mice infected with ∆glfA were still 
alive on day 13. A logrank test on wt and ∆glfA
survival data confirmed that the observed difference 
was statistically significant (P = 0.0004). The 
attenuation in virulence could clearly be attributed to 
the absence of glfA, since animals infected with the 
reconstituted wild type strain glfA* showed a survival 
pattern nearly identical to wt (no significant difference 
in logrank test, P = 0.559). Histological examination 
of lung tissue from mice infected with wt, ∆glfA and 
glfA* 5 days after inoculation showed evident fungal 
growth surrounding bronchioles and tissue penetration 
(Fig. 7). For each strain, inflammatory cells were 
rarely observed at the sites of infection.  
To correlate the delay in the onset and progression 
of mortality with a growth defect, fungal burden in 
lungs of infected mice was determined by quantitative 
PCR (Fig. 6B). Mice were treated and infected as 
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Figure 6 A) Survival of immunosuppressed mice infected intranasally with A. fumigatus wt (continuous), ∆glfA (dotted) or glfA* (dashed) 
and uninfected mice (dot-dashed). Each group consisted of 20 animals. B) Quantitative PCR determination of A. fumigatus burden 
(measured as conidial equivalents, see Material and Methods) in lung tissue from immunosuppressed mice infected with wt (continuous) or 
∆glfA (dotted). Each datapoint represents mean values obtained from three to five animals. Error bars indicate standard error of the mean. 
 
described above. After two, four and six days, 
animals were sacrificed and their lungs taken. DNA 
was isolated from homogenized lung tissue and 
fungal content determined by amplification of a part 
of A. fumigatus ribosomal DNA. As shown in figure 
6B, growth of ∆glfA was restricted in vivo when 
compared to wt, which was in agreement with the 
slower growth observed in vitro. 
 
 
DISCUSSION 
 
The essential role of the β1,3-glucan in cell wall 
organization and growth of several pathogenic fungi 
has been the basis for the development of the 
echinocandins (11). Likewise, inhibitors of chitin 
biosynthesis are currently explored as new antifungal 
drugs since chitin is an important structural element 
of the fungal cell wall (6). In contrast, although it is a 
major component of the cell wall and extracellular 
matrix, the role of galactomannan had not yet been 
investigated since the enzymes involved in its 
biosynthesis are unknown. Recently, we and others 
characterized the UDP-galactopyranose mutase 
(UGM) of various pathogenic eukaryotes including  
A. fumigatus (2,5). In prokaryotes, like in the 
protozoan Leishmania, this enzyme is the only route 
to the formation of UDP-Galf, the donor substrate of 
galactofuranosyltransferases, and thus controls the 
biosynthesis of all Galf containing molecules. 
Likewise, A. fumigatus UGM was found to be 
essential for the biosynthesis of galactomannan as 
well as some glycosphingolipids and glycoproteins. 
Like in other organisms (16,32), deletion of the glfA 
gene resulted in the complete absence of Galf, as 
shown for instance by the absence of reactivity to the 
antibody EB-A2.  
Besides demonstrating the lack of Galf in the ∆glfA 
mutant, our analyses provide useful structural 
information of A. fumigatus N-glycans. Treatment of 
wild type secreted proteins with PNGase F released 
galactofuranosylated high-mannose type N-glycans. 
The size of the oligosaccharides and presence of a 
single Galf residue is in agreement with previous 
studies in filamentous fungi (26,29). Moreover, 
analysis of these oligosaccharides after digestion by 
Jack bean- or T. reesei α1,2-mannosidase helps 
positioning the Galf residue. These data and the 
comparison with high-mannose standards suggest that 
the N-glycans from A. fumigatus secreted proteins 
resemble those of A. niger α-D-galactosidase and α-D-
glucosidase (45,44,49). These N-glycans might have 
simply arisen from trimming of the Glc3Man9GlcNAc2
precursor and substitution by a Galf
 
residue. Aspergilli
indeed contain several α1,2-mannosidase genes and 
trimming of high mannose glycans has been shown 
previously (52,13). Interestingly, Galf addition has 
been suggested to act as a stop signal for mannose 
addition in analogy to the role proposed for α1,3-
linked terminal mannose in Saccharyomyces 
cerevisiae (29,49). However, preventing the addition 
of galactofuranose does not result in an increased size 
of the oligosaccharides. On the contrary, 
Man5GlcNAc2 is the main oligosaccharide found in 
the ∆glfA mutant while GalfMan6GlcNAc2 is 
predominant in wild type. 
Although glfA deletion has been shown to be lethal 
in Mycobacterium smegmatis (32), the in vitro
viability of A. fumigatus ∆glfA mutant is unsurprising 
since Galf occupies a non-reducing terminal position 
in the molecules of this fungus. Hence, the absence of 
Galf does not perturb the basic organization of the cell 
wall, as would the absence of the underlying 
structures. Nevertheless, it resulted in marked 
alterations of the cell surface and notably a thinner 
cell wall as revealed by electron microscopy. The 
basis of this drastic change is unclear and difficult to 
attribute to a particular cell wall component since 
  A. fumigatus UDP-Galactopyranose Mutase 
            
                                                                                                                                                               32 EUKARYOTIC CELL, Aug. 2008, p. 1268–1277 Vol. 7, No. 8, doi: 10.1128/EC.00109-08 
Copyright © 2008, American Society for Microbiology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Periodic Acid Schiff stained lung sections of mice infected with A. fumigatus wild type (left), ∆glfA (middle) or glfA* (right). 
Fungal colonies appear purple/red. Infected sites are typically surrounded by areas of necrotic tissue but show no or hardly any infiltrating 
leukocytes. The scale bar represents 100 µm. 
GPI-/cell wall bound galactomannan, N-glycans, O-
glycans and GIPCs are affected by Galf deficiency. In 
other fungi, the loss of terminal sugar residues has 
sometimes been associated with reduced cell wall 
strength. For instance, a Schizosaccharomyces pombe 
mutant deficient in cell wall galactosylation displays 
morphological changes, attenuated growth and a 25-
35 % reduction in cell wall thickness (46).  
The structural changes originating from the glfA 
deletion are associated with slower growth indicating 
that Galf plays an important role in A. fumigatus 
morphogenesis. The temperature-sensitive growth 
defect at higher temperature displayed by the ∆glfA 
mutant is reminiscent to that observed in the ∆AfPmt1 
mutant, a mutant characterized by reduced O-
glycosylation (53). Interestingly, an influence of Galf 
deficiency on the growth rate was also observed in 
∆glfA mutants of Aspergillus nidulans and 
Aspergillus niger (10). Conversely glfA deletion had 
no effect on the in vitro growth of Leishmania 
parasites (16) highlighting that the role of Galf cannot 
be translated to every Galf containing organism. 
The ability to thrive at 37 °C is a characteristic of 
human pathogens that has been shown to correlate 
with virulence potential in the case of A. fumigatus 
(31). Consequently, mutations that affect the growth 
of fungi at mammalian body temperature are 
commonly associated with attenuated virulence (40). 
In this study, we observed slower growth of the A. 
fumigatus ∆glfA mutant in vitro but also in vivo using 
quantitative PCR. In agreement with this observation, 
the mutant was clearly attenuated in virulence 
showing a delay in both the onset and progression of 
mortality when tested in a low dose mouse infection 
model of invasive aspergillosis. An altered immune 
response caused by the different cell wall structure of 
the ∆glfA mutant may also contribute to the 
attenuation in virulence. However, no differences in 
adherence and uptake of wt and ∆glfA conidia by 
murine bone-marrow derived dendritic cells or in the 
production of TNF-α or IL-10 by infected murine 
bone-marrow derived macrophages were observed (K. 
Kotz, F. Ebel and F.H. Routier, unpublished data).  
The value of echinocandins in invasive aspergillosis 
treatment resides in their synergistic effects with 
azoles and amphotericin B. Similarly, chitin synthesis 
inhibitors demonstrate synergy with echinocandins 
and azoles (24). These synergistic effects that offer 
new options for combination antifungal therapy are 
most likely due to greater cell wall permeability. We 
did note an increase in susceptibility of the ∆glfA
mutant to several antifungal agents, notably to 
voriconazole. However, in the liquid culture 
conditions classically used for antifungal 
susceptibility testing, the fungus is not surrounded by 
extracellular matrix. This extracellular matrix that 
delays the penetration of drug is rich in 
galactomannan (3) and is probably altered in the ∆glfA
mutant as suggested by the compact appearance of 
colonies on agar plates. In vivo a greater increase in 
susceptibility of the ∆glfA mutant to drugs would 
therefore be expected. Besides the attenuated 
virulence, this suggests that inhibitors of UGM might 
be useful in antifungal therapy. The absence of Galf
biosynthesis in mammals would represent a 
considerable advantage for the development of 
antifungal drugs with selective toxicity.  
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Chapter 3 – A single UDP-Galactofuranose transporter is 
required for galactofuranosylation in Aspergillus 
fumigatus 
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Preface – About this manuscript 
This part of my work aimed at the identification of the assumed UDP-Galf transporter in A. fumigatus. 
For this purpose the A. fumigatus genome was searched using the BLAST algorithm with known 
nucleotide sugar transporter genes. Sixteen candidate genes were identified and one of them, glfB, 
was found closely located to the previously described glfA gene. The glfB cDNA was cloned and the 
GlfB protein overexpressed in S. cerevisiae. The golgi fraction of this yeast strain was subjected to a 
modified nucleotide sugar transport assay to demonstrate binding specificity of GlfB for UDP-Galf. 
An A. fumigatus glfB deletion mutant was generated (∆glfB) and analyzed with the methods described 
in detail in the previous chapter.   
My contributions to this manuscript comprised the identification of the candidate gene glfB and the in 
vitro transport/binding assays. Moreover, I assisted Jakob Engel, the shared first author, in the design 
of the experiments dedicated to characterize the molecular and macroscopic phenotype of the ∆glfB 
mutant. Prof. Routier and I wrote the paper. 
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SUMMARY  
Galactofuranose (Galf) containing 
molecules have been described at the cell 
surface of several eukaryotes and shown to 
contribute to the virulence of the parasite 
Leishmania major and the fungus Aspergillus 
fumigatus. It is anticipated that a number of 
the surface glycoconjugates such as N-glycans 
or glycolipids are galactofuranosylated in the 
Golgi apparatus. This raises the question how 
the substrate for galactofuranosylation 
reactions, UDP-Galf, which is synthesized in 
the cytosol, translocates into the organelles of 
the secretory pathway. Here we report the 
first identification of a nucleotide sugar 
transporter with specificity for UDP-Galf 
named GlfB.  In vitro transport assays 
established binding of UDP-Galf to GlfB and 
excluded transport of several other nucleotide 
sugars. Furthermore, the implication of glfB 
in the galactofuranosylation of A. fumigatus 
glycoconjugates and galactomannan was 
demonstrated by a targeted gene deletion 
approach. Our data reveal a direct 
connection between galactomannan and the 
organelles of the secretory pathway which 
strongly suggests that the cell wall bound 
polysaccharide originates from its GPI-
anchored form. 
 
 
INTRODUCTION 
The monosaccharide galactofuranose (Galf1) 
is an important constituent of the microbial cell 
surface (1). It occurs in structures essential for 
bacterial virulence or growth such as the O-
antigen of the outer membrane 
lipopolysaccharide or the mycobacterial 
arabinogalactan (2). In eukaryotes, Galf has 
principally been reported in glycoconjugates and 
polysaccharide of fungi and protozoan parasites 
(3) although the distribution of the glf gene 
encoding the UDP-Galf biosynthetic enzyme, 
UDP-galactopyranose mutase (UGM), suggests 
its presence in many lower eukaryotes (4,5). 
Amongst fungi, the cell wall of the opportunistic 
pathogen Aspergillus fumigatus is one of the 
best studied. In this organism, Galf has been 
found in the polysaccharide galactomannan (6), 
on glycoinositolphosphoceramides (7,8) and in 
N- and O-linked glycans of glycoproteins (9,10). 
In Aspergillus fumigatus like in the parasite 
Leishmania major, the generation of a mutant 
devoid of Galf resulted in attenuated virulence 
highlighting an important role of Galf for 
eukaryotic pathogens (11,12).  
Little is known about the Galf biosynthetic 
pathways in eukaryotes. Genetic and 
biochemical studies have shown that UDP-Galf 
arising from the action of UGM is essential for 
galactofuranosylation (12). This nucleotide 
sugar is most likely the substrate of specific 
galactofuranosyltransferases although genes 
encoding putative galactofuranosyltransferases 
have only been identified in trypanosomatid 
parasites (13,14). One of these putative 
transferases known as LPG1 is involved in the 
biosynthesis of the lipophosphoglycan (LPG) of 
Leishmania parasites and is localized in the 
Golgi apparatus (15). Similarly, enzymes 
involved in addition of terminal Galf to N-
glycans, O-glycans or glycolipids are assumed to 
be localized in this organelle. UDP-Galf 
biosynthesis however occurs in the cytosol (11) 
which makes translocation of UDP-Galf across 
the Golgi membrane necessary (fig. 1).  
Nucleotide sugar transporters (NSTs) are 
multi-transmembrane proteins present in all 
kinds of eukaryotic organisms. They consist of 
typically 8-10 transmembrane α-helices linked 
by short loops. Further structural information is 
very limited because efforts to obtain crystals for 
X-ray structure determination have been 
hindered by the high hydrophobicity of NSTs. 
Many NSTs have been functionally 
characterized in biochemical assays measuring 
incorporation of radioactive nucleotide sugars 
into membrane vesicles. These experiments led 
to the development of a mechanistic model, in 
which NSTs work as antiporters that export a 
nucleotide sugar molecule in exchange for an 
equally charged nucleoside monophosphate 
molecule (16).  
Because of their structural conservation, 
putative NSTs can be readily found by database 
mining. In humans, they belong to the SLC35 
(SoLute Carrier 35) family (17) which comprises 
ten characterized members and 13 proteins 
whose function is currently unknown. 
Phylogenetic classification identified 
subfamilies which contain all of the 
characterized SLC35 proteins, but do not allow 
classification of most of the SLC35 proteins 
with unknown function (18). Furthermore, 
substrate specificity is hardly conserved within 
NST subfamilies, thus it is generally not possible 
to infer substrate specificity from the level of 
sequence identity or phylogeny.  
  Aspergillus fumigatus UDP-Galf transporter 
  
  39 
NSTs are closely related to plastidic 
phosphate translocators (pPT) that include 
translocators for triose phosphate (TPT), 
phosphoenolpyruvate (PPT), glucose-6-
phosphate (GPT) and xylulose phosphate (XPT). 
Additionally, a variety of uncharacterized 
phosphate translocator-homologous proteins 
(PTh) are found in plant and other organisms 
including human (19). In this study, we describe 
the characterization of an Aspergillus fumigatus 
PTh protein with NST function and demonstrate 
its specificity for UDP-Galf. The importance for 
in vivo galactofuranosylation is shown by a 
targeted gene deletion approach. 
 
EXPERIMENTAL PROCEDURES 
Materials. Radiolabeled nucleotide sugars 
were purchased from PerkinElmer (UDP-[³H]-
Gal, UDP-[³H]-GlcNAc, UDP-[14C]-GlcA), 
American Radiolabeled chemicals (UDP-[³H]-
GalNAc, [³H]-UMP) and GE Healthcare (UDP-
[³H]-Glc). UDP-Galf was chemically 
synthesized (20).  
Strains, media, growth conditions. For 
protein expression, S. cerevisiae strain BY4741 
in which the gene for the ER UDP-GlcNAc 
transporter, YEA4, had been deleted (MATa; 
his3D1; leu2D0; met15D0; ura3D0; 
YEL004w::kanMX4; EUROSCARF, Frankfurt, 
Germany) was cultivated in SC minimal media 
[2 % glucose, 1.7 g/L DifcoTM Yeast Nitrogen 
Base w/o amino acids and ammonium sulfate 
(BD Biosciences), 5 g/L ammonium sulfate] 
supplemented with L-histidine (50 mg/L), L-
methionine (50 mg/L) and L-leucine (100 
mg/L). 
Aspergillus fumigatus clinical isolate D141 
was used in this study. For gene deletion 
purposes, a D141 strain deficient in non-
homologous end-joining (AfS35) was used (21). 
Strains were grown at 37 °C on Aspergillus 
minimal medium (AMM) containing 1 % D-
glucose as carbon source and 70 mM NaNO3 as 
nitrogen source. Phleomycin was added for 
selection purposes at 30 mg/L. 
Bioinformatic analyses. Transmembrane 
helix prediction was carried out using the 
ConPred II program (http://bioinfo.si.hirosaki-
u.ac.jp/~ConPred2) (22). For plant proteins, 
predicted transmembrane domains were obtained 
from the ARAMEMNON database 
(http://aramemnon.botanik.uni-
koeln.de/index.ep) (23). BLAST searches were 
performed using default parameter values with 
the low complexity filter switched off. 
Cloning of the glfB gene Total RNA was 
isolated from A. fumigatus mycelium and glfB 
mRNA was reversely transcribed into single-
stranded cDNA using primer JE28.All primer 
sequences are provided in Table 1. The glfB 
coding sequence was then amplified by PCR 
(JE26/JE28) and cloned  via BamHI/XbaI into 
plasmid vector pYEScupFLAGK (24).  
Protein expression in yeast, subcellular 
fractionation and in vitro transport assay. The 
glfB cDNA as well as the human UDP-Gal 
transporter cDNA (SLC35A2, isoform a) (25) 
were cloned into the plasmid vector 
pYEScupFLAGK (complementing uracil 
auxotrophy) for copper-inducible expression of 
N-terminally FLAG tagged proteins in yeast. S. 
cerevisiae spheroplasts were transformed using 
the lithium-acetate method described by 
Invitrogen. Transformants were selected on SC 
minimal media without uracil. For protein 
expression, transformants were grown in 1L-
cultures until A600 reached 0.8-0.9, expression 
was then induced by addition of 0.5 mM CuSO4 
(final concentration) and culture was continued 
for 2 h at 30 °C. 
Subcellular fractionation of yeast cells and 
in vitro transport assay were performed as 
previously described (24). Briefly, 50 µl Golgi 
vesicle preparations (containing typically 80 µg 
total protein) and 50 µl of 2 µM [³H]-labeled 
nucleotide sugar or [³H]-UMP (0.37 kBq/µl) in 
assay buffer (10 mM Tris-HCl, pH 7.0; 0.8 M 
sorbitol; 2 mM MgCl2) were incubated for 30 s 
at 30 °C. For competition assays, the assay 
buffer contained in addition 100 µM unlabeled 
nucleotide sugar (26). Reactions were stopped by 
dilution with 1 ml of ice-cold assay buffer. The 
vesicle suspension was then filtered through a 
mixed cellulose ester membrane (MFTM 
membrane filters, 0.45 µm, Millipore, Bedford, 
MA). Vesicles adhering to the filters were 
washed three times with 2 ml of ice-cold assay 
buffer and the radioactivity retained on the 
membrane was measured by liquid scintillation. 
Generation of A. fumigatus ∆glfB mutant 
strain. The 5’ and 3’ flanking regions (1.5 kb 
each) of A. fumigatus glfB coding sequence were 
amplified from genomic DNA by PCR with 
primers JE15/JE14 and JE20/JE17 respectively 
and linked by fusion PCR to a ble/tk cassette 
conferring resistance to phleomycin (27) 
amplified by JE06/JE07. From this construct, a 
second PCR (JE18/JE19) yielded the final 
deletion construct. Sequence integrity was 
verified after cloning into pCR2.1-TOPO 
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(Invitrogen). Polyethylene glycol mediated 
fusion of protoplasts was carried out as 
described in (34). Transformants were grown on 
AMM plates containing 1.2 M sorbitol as 
osmotic stabilizer under appropriate selection 
conditions and singled out twice before further 
analysis. Accurate gene deletion and 
reconstitution were confirmed by southern 
hybridisation. Southern probes were amplified 
from genomic DNA using primer pairs 
JE21/JE22, JE25/JE24 and PS20/PS21. All 
primer sequences are provided in Table 1. 
Western Blots. Cell wall glycoproteins and 
soluble polysaccharides were extracted from 
30 mg ground A. fumigatus mycelium by 
incubation in 1 mL sample buffer (15 % 
glycerol, 100 mM Tris/HCl pH 6.8, 1.5 % SDS, 
0.25 % β-mercaptoethanol, 0.025 % 
bromophenol blue) for 12 min at 95 °C. 20 µl of 
the supernatant were separated on a 10 % SDS-
polyacrylamide gel and transferred to 
nitrocellulose membranes. The monoclonal 
antibody EB-A2 (39) conjugated to horseradish 
peroxidase (HRP) from the Platelia Aspergillus 
Test (Bio-Rad, Hercules, CA, USA) or HRP-
coupled lectin Concanavalin A (ConA, Sigma-
Aldrich) were used in a 1:50 dilution or at 0.2 
µg/mL respectively. HRP activity was visualized 
by an enhanced chemiluminescence system 
(Pierce). 
Purification and analysis of 
glycosylinositolphosphoceramides (GIPCs). 
GIPCs were extracted from 0.5 g mycelium and 
purified as previously described (12). Purified 
GIPCs were redissolved in 20 µl MeOH. High 
performance thin layer chromatography and 
immunostaining with the monoclonal antibody 
MEST-1 were carried out as described (7) using 
2 µl for immunostainings and 18 µl for 
orcinol/H2SO4 stainings. 
N-glycan analysis. N-glycan preparation 
and separation was carried out as described 
previously (28). Glycoproteins from 12 mL (40x 
300 µl) A. fumigatus culture supernatant were 
transferred to Immobilon P Multiwell plates 
(Millipore). After peptide:N-glycanase (PNGase 
F) mediated N-glycan release and 8-amino-
1,3,6-pyrene-trisulfonic acid (APTS) labelling 
N-glycans were separated on a capillary 
electrophoresis DNA Sequencer (ABI PRISM® 
3100-Avant Genetic Analyzer, Applied 
Biosystems, Foster City, CA, USA). Reference 
glycans were purchased from Dextra 
Laboratories (Reading, UK). 
Growth assay. For radial growth 
measurement, a 5 µl drop containing 10,000 A. 
fumigatus conidia in PBS was placed in the 
centre of an AMM agar plate. Plates were 
incubated at various temperatures and colony 
diameters were measured twice daily. 
 
RESULTS 
Selection of a UDP-Galf transporter 
candidate gene – BLAST searches of the A. 
fumigatus genome (29) with various 
characterized NST protein sequences identified 
16 putative NST genes (Suppl Table 1) One of 
them (AFUA_3G12700) is adjacent to the 
recently identified glfA gene (AFUA_3G12690) 
encoding the UDP-Galf biosynthetic enzyme 
UGM, and was thus considered as a reasonable 
candidate since clustering of functionally related 
genes is sometimes observed in A. fumigatus 
(e.g. the siderophore genes sidF, sidD and mirB) 
(30). This gene will be further referred to as glfB 
because of its implication in 
galactofuranosylation as demonstrated below. 
Interestingly, all fungi from the subphylum 
Pezizomycotina whose genome has been fully 
sequenced display a clear homolog of glfB 
clustered with glfA. When present in 
basiodiomycota (e.g. Cryptococcus neoformans), 
these two genes are more distant and may be 
found on different chromosomes. In 
A. fumigatus, the predicted GlfB protein 
comprises 400 amino acids and shares up to 40 
% amino acid identity with uncharacterized 
Arabidopsis phosphate translocator homologs. 
The most similar protein with known function is 
the plant UDP-Gal transporter AtUDP-GalT1 
(At1g77610) (31) that displays 21% identity 
with GlfB. The UDP-Gal transporters AtUDP-
GalT2 (At1g76670) and AtNST-KT1 
(At4g39390) (31,32), and the uncharacterized 
SLC35C2 and SLC35E3 are more distantly 
related and show 14 to 19 % identity with GlfB. 
Finally, the human GDP-Fuc transporter is the 
closest characterized transporter of the SLC35 
family (12 % identity). An alignment of GlfB 
with these sequences is presented in figure 2. 
This multiple sequence alignment underlines the 
conservation of two lysine residues (GlfB K59 
and K294) that have been proposed to be 
involved in substrate binding (19,33). GlfB was 
predicted to contain eleven transmembrane 
helices of which the first ten aligned well with 
the predicted transmembrane helices of its 
homologs and other NSTs (fig. 2). We thus 
hypothesized that glfB encoded a NST and in 
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line with its location in the genome speculated 
about a specificity for UDP-Galf. 
In vitro Transport and binding assays– 
Uptake of radioactive nucleotide sugars by 
Golgi-enriched vesicles isolated from yeast 
expressing a putative NST is a method of choice 
to determine substrate specificity. Unfortunately, 
since UDP-Galf was not available in a 
radiolabeled form, it could not be directly tested 
in this in vitro assay system. Nevertheless, the 
transport of UDP-Gal, UDP-GlcNAc, UDP-
GalNAc or UDP-GlcA could be excluded. 
Indeed, the uptake of these nucleotide sugars by 
Golgi vesicles isolated from yeast cells 
expressing GlfB or mock transformed was 
virtually absent (background levels of 1.0 to 1.7 
pmol mg-1 min-1) while an endogenous UDP-Glc 
transport of approximately 7 pmol mg-1 min-1 
demonstrated the quality of the Golgi vesicles 
preparation. Additionally, transfection of CHO-
Lec8 cells with GlfB resulted in Golgi 
expression of the protein but did not restore 
galactosylation of the surface glycoconjugates 
confirming absence of UDP-Gal transport (data 
not shown). 
To assess UDP-Galf binding, we then 
evaluated the ability of unlabeled UDP-Galf (34) 
to inhibit the uptake of radioactive UMP, the 
postulated counter substrate of GlfB (fig 3A). 
For this purpose, Golgi vesicles obtained from 
cells expressing either GlfB or the human UDP-
Gal transporter were incubated with 1 µM [³H]-
UMP and 100 µM unlabeled UMP, UDP-Galf, 
UDP-Gal or UDP-GlcNAc. In GlfB containing 
vesicles, the addition of UDP-Galf resulted in an 
80 % inhibition of the [³H]-UMP transport and 
was thus comparable to addition of unlabelled 
UMP (88 % inhibition). In contrast, UDP-
GlcNAc and UDP-Gal slightly affected the UMP 
uptake indicating a limited binding of these 
nucleotide sugars to GlfB. Unfortunately, since 
UDP-Galf is rather unstable, contamination of a 
UDP-Galf solution by UMP is difficult to avoid 
(35) and was in this case estimated to 6-7 % by 
HPLC (36) (Suppl fig 1). This contaminating 
UMP explains the 50 % decrease of [³H]-UMP 
uptake observed with vesicles expressing the 
UDP-Gal transporter since a comparable 
inhibition is observed with 8 µM unlabelled 
UMP (Fig. 3B). In contrast, inhibition of GlfB 
mediated [³H]-UMP uptake by the contaminated 
UDP-Galf solution was significantly higher than 
the one observed with 8 µM UMP (P = 0.011, t 
test) indicating that part of the inhibition 
observed is actually due to UDP-Galf binding.  
Deletion of glfB in A. fumigatus – To prove 
UDP-Galf transport activity in vivo, evaluation 
of the effect of glfB loss on 
galactofuranosylation of glycoconjugates in 
A. fumigatus was undertaken. For this purpose a 
glfB deletion cassette was constructed by 
double-joint PCR (37) containing the selectable 
phleomycin resistance gene ble (27) flanked by 
up- and downstream regions of the glfB coding 
sequence. A. fumigatus wild type protoplasts 
were transformed with the linearized cassette for 
exchange of the genomic glfB coding sequence 
for the phleomycin resistance gene by 
homologous recombination (fig. 4A). 
Transformants were selected for phleomycin 
resistance and gene replacement was confirmed 
by Southern Blot analysis (fig. 4B). A single 
strain was chosen for further analysis and named 
∆glfB.  
Analysis of galactofuranosylation in ∆glfB 
– Since N-glycosylation of proteins is known to 
take place along the secretory pathway and 
requires various NSTs, we first concentrated on 
this modification. Proteins from A. fumigatus 
culture supernatants were immobilized on PVDF 
membranes and N-glycans were released by 
peptide:N-glycanase treatment. After labeling 
with the negatively charged fluorescent dye 
APTS, N-glycans were separated by capillary 
electrophoresis on a DNA sequencer (fig. 5A). 
In the wild type electropherogram (top panel), 
the peaks labelled 1a to 5a can be assigned to 
high-mannose type N-glycans bearing a single 
Galf residue (GalfMan5-9GlcNAc2) according to 
previous findings (10,12). These Galf-containing 
glycans were completely absent from the ∆glfB 
N-glycan electropherogram (middle panel) that 
exclusively displays non galactofuranosylated 
N-glycans (peaks 1-5) co-migrating with 
Man5-9GlcNAc2 standards (lower panel, fig. 5B). 
This finding demonstrates the requirement of 
GlfB for galactofuranosylation of N-glycans.  
The contribution of GlfB to glycolipid 
biosynthesis was also analysed by testing their 
reactivity to the monoclonal antibody MEST-1 
(38). This antibody reacts specifically with β1-6-
Galf found on several glycosphingolipids of A. 
fumigatus (fig 5C, left) (7).  However, 
glycosphingolipids extracted from A. fumigatus 
∆glfB mycelium and separated by HPTLC were 
not stained with MEST-1 indicating absence of 
β1-6 linked galactofuranose in these molecules.  
As loading control, carbohydrates were stained 
with orcinol/sulfuric acid (fig. 5C, right).  
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Finally we tested for reactivity of cell wall 
components towards the Galf-specific 
monoclonal antibody EB-A2 (39). A 
tetrasaccharide of β1-5-linked Galf has been 
described as main epitope of EB-A2 (39). This 
structure is part of the cell wall polysaccharide 
galactomannan which can be either linked to the 
cell wall β1-3/6-glucan (6) or to a GPI-anchor 
(40). Also N-glycans with a single terminal Galf 
have been reported to be recognized by EB-A2 
(10). Aqueous extracts of wild type A. fumigatus 
mycelium separated on a polyacrylamide gel and 
transferred to a nitrocellulose membrane 
strongly bound EB-A2, while in case of the 
∆glfB mutant, binding was totally absent (fig. 
5D, left). In contrast, staining with the mannose-
specific lectin Concanavalin A appeared slightly 
stronger for ∆glfB than for wild type, suggesting 
a higher exposure of cell surface mannan 
structures as previously observed with the ∆glfA 
mutant indicating a higher exposure of cell 
surface mannan structures (fig. 5D, right)(12). 
Thus, the surface glycoconjugates of ∆glfB 
resemble closely those of the Galf-deficient 
∆glfA mutant (12) and suggests a complete loss 
of galactofuranosylation capacity in the ∆glfB 
mutant.   
Growth and thermotolerance of the ∆glfB 
mutant – Galf deficiency has been shown to 
induce an altered culture morphology 
accompanied by a substantial growth defect in A. 
fumigatus (12). This effect was more 
pronounced at higher temperatures than the 
standard growth temperature of 37 °C indicating 
a decreased resistance to temperature stress. 
Indeed, radial colony growth of the ∆glfB 
mutant was found to be 45 % slower than wild 
type at 37 °C and 66-67 % slower at 42 or 47 °C 
(fig. 6) in agreement with the observations for 
the ∆glfA mutant (12).  
 
DISCUSSION 
This report describes the first identification 
of a nucleotide sugar transporter with specificity 
for UDP-Galf. The protein called GlfB because 
of its implication in galactofuranose metabolism 
was selected from its homology to other member 
of the NST family, its phylogenetic 
classification as well as the location on 
chromosome 3 directly downstream of the glfA 
gene which encodes the UDP-Galf biosynthesis 
enzyme UGM (12). It is a 400 amino acid 
protein with 11 predicted transmembrane 
helices. This represents a particularity of the 
GlfB protein since NSTs classically exhibit 8 to 
10 predicted hydrophobic domains and follow an 
experimentally determined model in which both 
the N-and C-terminus are situated on the 
cytoplasmic side of the organelle (41).  
Remarkably, filamentous fungi of the 
subphylum Pezizomycotina, including many 
human or plant pathogens, all seem to exhibit 
adjacent glfA and glfB genes and the presence of 
Galf has been reported in many species of this 
subphylum. These genes are also found in a few 
basidiomycota such as the human pathogen 
Cryptococcus neoformans but are absent from 
other fungi, notably from yeasts. Thus, Galf 
seems particularly important for filamentous 
fungi. Indeed several studies have already shown 
the role of this monosaccharide for growth, 
hyphal morphology and sporulation of 
Aspergillus species (12,42,43). We thus 
speculate that Galf plays major roles in the 
hyphal development and/or reproduction of all 
filamentous fungi of Pezizomycotina and thus 
has been maintained during evolution.  
To address the function of a nucleotide 
sugar transporter, two approaches are commonly 
used. Complementation of a mutant strain or cell 
line not only provides a way to determine NST 
function in vivo, but also allows identification of 
the underlying gene(s) by expression of a cDNA 
library combined with sibling selection (31). 
Alternatively, NST substrates can be identified 
by measuring transport of radiolabeled 
nucleotide sugars into vesicles, either prepared 
from cell lysates or artificially reconstituted 
proteoliposomes (44,45). Because of the 
unavailability of a UDP-Galf transporter 
deficient mutant or cell line and radioactive 
UDP-Galf, we opted for targeted gene deletion 
of candidate genes in the opportunistic fungus 
Aspergillus fumigatus. This approach was 
enabled by the restricted number of candidate 
genes, the existence of a haploid stage that 
facilitates the isolation of clones by molecular 
techniques and a comprehensive knowledge of 
the galactofuranosylated structures in this 
organism. Targeted replacement of the most 
promising candidate gene, glfB, led to the 
absence of Galf bringing a direct evidence of its 
involvement in Galf metabolism. 
The specificity of GlfB for UDP-Galf was 
established by an indirect assay showing 
competitive inhibition of [³H]-UMP transport by 
GlfB with unlabeled UDP-Galf. In addition, the 
transport of several other nucleotide sugars was 
excluded using a direct in vitro transport assay 
suggesting that GlfB is highly specific. In 
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particular the absence of UDP-Gal transport 
which was confirmed by the inability of glfB to 
complement the CHO cell line Lec8 indicates 
that the transporter is able to discern the ring 
conformation of the monosaccharide. Vice versa, 
our data show that the human UDP-Gal 
transporter used as control in this study does not 
recognize UDP-Galf. Similarly Leishmania 
major UDP-Gal transporters LPG5A and 
LPG5B appear to be specific for the pyranic 
form of galactose since their concomitant 
deletion results in the synthesis of 
glycoconjugates containing Galf but devoid of 
galactopyranose (46). The obvious difference in 
the three-dimensional structure of the furanic 
and pyranic rings certainly plays a role in the 
ability of these NSTs to differentiate the two 
cyclic forms. Initially NSTs were thought to be 
monospecific. However, several NSTs have now 
been shown to be multifunctional in vitro and 
usually recognize sugars activated with the same 
nucleotide which led to the assumption that the 
nucleotide part is a major player in recognition. 
With the exception of Fringe Connection (47), 
which is thought to be a general UDP-sugar 
transporter, the specificity of NSTs is generally 
restricted to a few related nucleotides sugars 
demonstrating that the sugar part also plays a 
significant role in the recognition.  
Detailed analyses of A. fumigatus ∆glfB 
total extract and purified glycoconjugates 
revealed the complete absence of 
galactofuranose in N-glycans, glycolipids as 
well as galactomannan. It can be inferred from 
this result that GlfB is the only NST in A. 
fumigatus capable of UDP-Galf transport. In this 
organism Galf is capping the N-glycans and 
glycolipids. Galactofuranosylation of these 
molecules was therefore expected to occur in the 
Golgi apparatus and thus depend on import of 
UDP-Galf in this organelle as observed. The lack 
of Galf in galactomannan was however less 
predictable since its biosynthesis is currently 
unknown. Recently, we demonstrated that the 
terminal sugar of this polysaccharide arises from 
UDP-Galf synthesized in the cytoplasm by UGM 
(12). Galactomannan is either linked to the 
membrane by a GPI anchor, covalently bound to 
the cell wall β1,3/1,6-glucan or secreted in the 
environment (6,40). Since they present the same 
carbohydrate structure, it has been postulated 
that these three forms of the polysaccharide 
share a common biosynthetic pathway. By 
analogy to the biosynthesis of the Leishmania 
GPI-anchored polysaccharide LPG (15), we 
assumed that the biosynthesis of the GPI-linked 
galactomannan takes place in the Golgi 
apparatus. The total absence of EB-A2 staining 
in the ∆glfB mutant indicative of the absence of 
all form of galactomannan supports this location. 
Galactomannan would then be transferred to the 
β1,3/1,6-glucan from the GPI-anchored polymer 
as it has been proposed for some GPI-anchored 
proteins in ascomycetous yeasts (48). The 
secreted form would arise from enzymatic 
cleavage of surface galactomannan. Our data 
demonstrating absence of galactofuran in the 
∆glfB mutant establish a clear link between 
galactomannan including the cell wall bound 
form and the secretory pathway and thus 
strongly support this model. In contrast, the 
synthesis of α1-3-glucan, β1-3-glucan and chitin 
seems to occur at the plasma membrane (49). 
In agreement with the complete absence of 
Galf in glycoconjugates and galactomannan, the 
growth phenotype of the glfB gene deletion 
mutant resembles closely the one of the 
previously described Galf-deficient ∆glfA (12). 
In the case of the ∆glfA, the growth defect was 
correlated with a reduction of virulence. It can 
thus be extrapolated that glfB is most probably 
required for full virulence of the fungus. Another 
example of nucleotide sugar transporter 
implicated in pathogenicity and restricted to 
certain organisms is the Golgi GDP-Man 
transporter. Deletion of this NST led to 
avirulence of the parasite Leishmania major (50) 
and is lethal in Saccharomyces cerevisiae, 
Candida albicans, and Candida glabrata (51-
53). In the latter organisms, Golgi 
mannosylation comprises N-glycan outer chain 
elongation, O-mannosylation of proteins and 
GIPC biosynthesis. The Aspergillus fumigatus 
genome contains a clear GDP-Man transporter 
homolog (AFUA_5G05740) whose importance 
is difficult to predict. It has recently been shown 
that protein O-mannosylation is dispensable in 
this fungus but required for cell wall stability 
and full virulence (54,55). Yet the importance of 
N-glycan branching and elongation, and 
mannosylation of GIPCs, is currently 
undetermined. The absence of Galf is however 
not sufficient to abolish growth of A. fumigatus 
as shown previously and confirmed in this study. 
Even chitin, a polysaccharide which is believed 
to contribute to the rigidness of the fungal cell 
wall is not strictly essential for S. cerevisiae 
(56,57). Therefore, therapeutic strategies 
directed against cell wall biosynthesis will likely 
have to address several targets to be successful.  
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FOOTNOTES 
1
 Abbreviations used in this paper: Galf, Galactofuranose, Gal, Galactopyranose; UDP, Uridine-5’-
diphosphate; UGM, UDP-galactopyranose mutase; NST, nucleotide sugar transporter; GlcNAc, N-
Acetylglucosamine; GlcA, Glucuronic acid; GalNAc, N-Acetylgalactosamine; Glc, Glucose; UMP, 
Uridine-5’-monophosphate; ER, Endoplasmic Reticulum; AMM, Aspergillus Minimal Medium. 
2
 The glfB mRNA sequence of Aspergillus fumigatus D141 has been deposited in the GenBank 
database under GenBank Accession Number FJ746723. 
 
 
 
TABLES 
 
Table 1 DNA primer sequences for PCR 
Primer Sequence (5' -3'), restriction sites underlined Description (restriction site)  
JE06 TCGAGATCTTTCGACACTG forward primer ble/tk cassette 
JE07 CTAGAAAGAAGGATTACCTC reverse primer ble/tk cassette 
JE14 TCGACGTATTTCAGTGTCGAAAGATCTCGATGTGAAGAGTTGACTCTGGT 
reverse primer 5' flanking region +30 nt ble/tk 
cassette overlap 
JE15 GATGGAGAGTACGTATAACG forward primer 5' flanking region 
JE17 CGAAACTGTTGCGTTCTGTCC reverse primer 3' flanking region 
JE18 CAAGCTAGAGTAACCTGTCGAT forward primer nested PCR 
JE19 TATCCTTCGACGCTTCACTG reverse primer nested PCR 
JE20 CACTTGTTTAGAGGTAATCCTTCTTTCTAGGCTGGGAATGCGTAAAGAAAATG 
forward primer 3' flanking region +30 nt ble/tk 
cassette overlap 
JE21 CTCCGTCCGGTAGATAGGCACTGG forward primer Southern Blot probe 1 
JE22 GCCCGAAAATCAGACAAGCAGAGA reverse primer Southern Blot probe 1 
JE24 CCGGTGCGAGGATTGATAAGTGTC reverse primer Southern Blot probe 2 
JE25 CGGATTCACCCTCTTAACCACCTTC forward primer Southern Blot probe 2 
JE26 GCAAGGATCCAGTAACGAAGGAGAAAAAGCC forward primer glfB cDNA (BamHI) 
JE28 CGAGTCTAGATTACGCATTCCCAGCAGT reverse primer glfB cDNA (XbaI) 
PS20 AAGGTCGTTGCGTCAGTCCA forward primer Southern Blot probe 3 
PS21 TCGATGTGTCTGTCCTCC reverse primer Southern Blot probe 3 
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FIGURES 
 
Figure 1  
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Schematic model of galactofuranosylation. UDP-Galactofuranose (UDP-Galf) is synthesized from 
UDP-Galactopyranose (UDP-Gal) (1) and translocated via an antiporter into the Golgi in exchange for UMP (2). 
Galactofuranosyltransferases transfer Galf moieties from UDP-Galf on various glycoconjugates (3) and UDP is 
converted to UMP by a nucleoside diphosphatase (4). 
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Figure 2 
                                                     __________I__________        ___________II_________                                                        
                       10         20        30        40        50        60          70        80                         
              ....|....|....|.. ..|....|....|....|....|....|....|....|....|....|...  .|....|....|....|.. 
Af GlfB       msnegekarvsgevsrp-eptlptvnpaveksepskptfHPAVYVSLWIALSSSVILFNKhildyaqfR--FPIILTTWHLAFATFMTQV  
AT4G32390     mgkgg--alsdgvikK---------------------ILLSYTYVAIWIFLSFTVIVYNkyildkkmynwPFPITLTMIHMAFCSSLAVI  
At UDP-GalT1  meegs--------------------------------MFRSLLAILQWWGFNVTVIIMNKwifqkldfK--FPLSVSCVHFICSSIGAYI  
At UDP-GalT2  mekpesekks---------------------------aVSDVGAWAMNVISSVGIIMANKQlmsssgFGFGFATTLTGFHFAFTALVGMV  
At NST-KT1    mfkkmsattsktdqk----------------------aALDIASWLFNVVTSVGIILVNKAlmat--ygfsfATTLTGLHFGTTTLLTTF  
Hs SLC35C2    mgrwaldvaflWK------------------------AVLTLGLVLLYYCFSIGITfynkwltksfhFPLFMTMLHLAVIFLFSALSRal  
Hs SLC35E3    mallvdrvrg---------------------------hwRIAAGLLFNLLVSICIVFLNKwiyvyhgfp---nMSLTLVHFVVTWLGLYI  
Hs GDP-FucT1  mnraplkrsrilhmaltgasdpsaeaeangekpfllralqIALVVSLYWVTSISMVFLNKYlldspslrldtpifVTFYQCLVTTLLCKG  
 
 
              _                       __________III____  __        _________IV________        _______V__ 
                90       100         110       120       130       140       150       160       170          
              ..|....|....|....|...  .|....|....|....|....|....|....|....|....|....|....|....|....|....| 
Af GlfB       Lartttlldgrktvkmtgrvy--lRAIVPIGLFFSLSLICGNVTYlylsvaFIQMLKATTPVAVLLATWAMGmapvnlKVLFNVAVIVIG  
AT4G32390     LIKvfkivep---vsmsrDTY--IRSVVPIGALYSLSLWLSNSayiYLSVSFIQMLKALMPVAVYSIGVllkkesfKSETMTNMLSISFG  
At UDP-GalT1  VIKvlklkp---livvdpedr--wrRIFPMSFVFCINIVLGNVSLRYipvsfmqtiksftpattvvlqwlvwrkyFDWRIWASLVPIVGG  
At UDP-GalT2  snatg--------lsaskhvP--LWELLWFSIVANISIAAMNFSLmlnSVGFYQISKLSMIPVVCVLEWILhskhyckevKASVMVVVIG  
At NST-KT1    LTWLG--------yiqpsqlp--wPDLLKFVLFANFSIVGMNVSLMWnsvGFYQIAKLSMIPVSCLLEVMLDNvrysRDTKLSILLVLAG  
Hs SLC35C2    vqcsshrar----vvlswady--lrrvaptALATALDVGLSNWSFLYVTVSlYTMTKSSAVLFILIFSLIFKLeeLRAALVLVVLLIAGG  
Hs SLC35E3    CQKLd--------ifapkslp--pSRLLLLALSFCGFVVFTNLSLqnntigTYQLAKAMTTPVIIAIQTFCYqktfsTRIQLTLIPITLG  
Hs GDP-FucT1  LSALAAccpgavdfpslrldlrVARSVLPLSVVFIGMITFNNlclkYVGVAFYNVGRSLTTVFNVLLsylllkqtTSFYALLTCGIIIGG  
 
 
              _______     _________VI________                            _VII_________      
                 180          190       200       210       220        230       240           250            
              ....|..   ..|....|....|....|....|....|....|....| ....|....|....|....|....|..    ..|....|.. 
Af GlfB       VVIASFG---eiKFVFIGFLFQIGGIVFEATrlvmvqrllssaefkmd-plVSLYYFAPVCAVMNGVTALFVevpn----ltmghiynvg  
AT4G32390     VAIAAYG---EAkfdtWGVMLQLGAVAFEATRLVLIQILltskginln-pITSLYYVAPCCLVFLFFPWIFVElpi----lretssfHFD  
At UDP-GalT1  ILLTSVT---ElsfNMFGFCAALFGCLATSTKTILAEsllh--gykfd-sinTVYYMAPFATMILGIPALLLEGSgilswfeAHPAPWSA  
At UDP-GalT2  VGICTVT---DVKVNAkgficactavfstslqqisigslqk--kysvg-sfellsKTAPIQAISLLICGPFVDYLlsgkfistyqMTYGA  
At NST-KT1    VAVCTVT---DVsvnLNGFLAAAIAVWSTALQQYYVHylqr--kyslg-SFNLLAHTAPVQAASLLLVGPFLdywltnqrvdAYNFSFVS  
Hs SLC35C2    LFMFTYk---stqfnVEGFALVLGASFIGGIRWTLTqmllqkaelglqnpidtmfHLQPLMFLGLFPLFAVFEGLHlstsekifrfqdtG  
Hs SLC35E3    VILNSYY---DvkfNFLGMVFAALGVLVTSLYQVWvgakqh--elqvn-smqllyYQAPMSSAMLLVAVPFFEPVFg-eggifgpwsvSA  
Hs GDP-FucT1  FWLGVDqegaegtlSWLGTVFGVLASLCVSLNAIYttkvlp----avdgsiwrltfynnVNACILFLPLLLLLGELQALRdfaqlgsahf  
 
 
              __________VIII___________       ________IX_________            ______X_ _______  
               260            270       280       290       300        310       320       330       340             
              ..|....     |....|....|....|....|....|....|....|....|.... |....|....|....|....|....|....|. 
Af GlfB       VWTLLAN-----AVVAFLLNVSVVFLigktssLVMTLCGVLKDILLVAASMMIwqtp-vTPLQFFGYSIALIGLVYYKLGgdkireyagq  
AT4G32390     FVIFGTN-----SVCAFALNLAVFLlvgktsALTMNVAGVVKDWLLIAFSWSVIkDT-VTPLNLFGYGLAFLGVAYYNHc--klqalkak  
At UDP-GalT1  LIIILSS-----GVLafcLNFSIFYVIHSTTAVTFNvagNLKVAVAVMVSWLIFRNP-isyMNAVGCGITLVGCTFYG-----Yvrhmls  
At UDP-GalT2  IFCILLS-----CALAVFCNisqylcigrfsaTSFQVLGHMKTVCVLTLGWLlfdse-mtFKNIAGMAIAIVGMVIYSWAvdiekqrnak  
At NST-KT1    LFFLILS-----CSIAVGTNlsqficigrftAVSFQVLGHMKTILVLVLGFTFFgkeGLNLQVVLGMLIAILGMIWYG---------NAs  
Hs SLC35C2    LLLRVLGSLFLGGILAFGLGfsefllvsrtSSLTLSIAGIFKEVCTLLLAAhllgdq-islLNWLGFALCLSGISLHVA----LKAlhsr  
Hs SLC35E3    LLMVLLS-----GVIAFMVNLSIYwiigntspvtyNMFGHFKFCITLFGGYVLFKDP-LSINQALGILCTLFGILAYT-------hfkls  
Hs GDP-FucT1  wgmmtlg-----glfgfaigyvtglqikftsplthnvsgtakacaqtvlavlyyeet-ksflwwtsnmmvlggssayt-----------w  
 
 
                              __________XI_________ 
                     350       360       370       380       390       400         
              ...|....|....|....|....|....|....|....|....|....|....|....| 
Af GlfB       anrswaeyganhpaqrKSIIIGAVVLIFFLLIGSMAPsyapesvdkvkgmlggatagna  
AT4G32390     daqkkvqqgdeeeagk-----------lleereseaaakrneted  
At UDP-GalT1  qqtpgtprtprtprsk---------------mellplvnndklegkv  
At UDP-GalT2  stphgkhsmtedeikl-----------lkegvehidlkdvelgdtkp 
At NST-KT1    skpggke-rrslsipi-----------tks----qklsetnesdekv  
Hs SLC35C2    gdggpkalkglgsspd-----------lelllrssqreegdneeeeyfvaqgqq  
Hs SLC35E3    eqegsrsklaqrp  
Hs GDP-FucT1  vrgwemkktpeepspk----------------------dseksamgv  
 
 
Figure 2 Multiple sequence alignment of Aspergillus fumigatus (Af) GlfB and related proteins from 
Arabidopsis thaliana (At) and humans (Hs) with prediction of transmembrane helices. The Arabidopsis 
uncharacterized protein encoded by the gene AT4G32390 and UDP-Gal transporter AtUDP-GalT1 are the 
closest GlfB homologs while the plant UDP-Gal transporters  At UDP-GalT2 and At NST-KT1, the human 
proteins SLC35C2 and SLC35E3 and the characterized GDP-Fucose transporter (SLC35C1) are more distantly 
related. Conserved residues, black shading; similar residues, dark-grey shading; predicted transmembrane 
domains, capital letters and light-grey shading; Roman numbers, predicted transmembrane domains for GlfB.      
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 UDP-Galf binds to GlfB. A) [³H]-UMP uptake by Golgi vesicles isolated from yeast expressing GlfB 
(black bars) or the human UDP-Gal transporter (grey bars) in absence or presence of a 100-fold molar excess of 
unlabelled UMP, UDP-Galf (containing 7 % UMP), UDP-Gal or UDP-GlcNAc. B) Comparison of [³H]-UMP 
uptake in presence of a 100-fold molar excess UDP-Galf containing 7 % UMP or an 8-fold molar excess UMP. 
Each value represents the average of three independent experiments with duplicate measurements. ns, not 
significant. 
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Figure 4 
 
 
 
 
 
 
 
 
 
 
Figure 4 Gene replacement of glfB in Aspergillus fumigatus. A) Strategy for the targeted replacement of glfB by 
the ble/tk selection marker cassette mediated by homologous recombination (thick black bars). The positions of 
probes (1-3) used for Southern Blot hybridisation along with respective restriction fragments (size in kb) are 
indicated. B) Southern Blots of genomic DNA digested with indicated restriction enzymes and hybridized to 
three different digoxigenin-labelled probes.  
wt, wild type; ble/tk, phleomycin resistance/thymidine kinase fusion gene; P, A. nidulans gpdA promoter; T, A. 
nidulans trpC terminator; glfA, UDP-galactopyranose mutase coding sequence 
 
 
  Aspergillus fumigatus UDP-Galf transporter 
  
  52 
Figure 5 
 
 
 
 
 
 
 
 
Figure 5 The Aspergillus fumigatus ∆glfB mutant lacks Galf A) Electropherograms of fluorescently labelled N-
glycans enzymatically released from secreted glycoproteins of A. fumigatus wild type (wt) and the ∆glfB 
mutant. Commercial oligosaccharides (Dextra Laboratories) served as reference (Ref.). The x-axis was 
calibrated to the fragment sizes of the GeneScan-500 ROX standard (Applied Biosystems). B) Schematic 
structures of reference oligosaccharides. Black squares, N-acetylglucosamine; grey circles, mannose. C) 
Glycoinositolphosphoceramides (GIPCs) extracted from A. fumigatus mycelium, separated by HPTLC and 
stained with either the Galf(β1-6/ β1-3)-specific antibody MEST-1 (left) or with orcinol/H2SO4 (right). The 
black line indicates the loading spot. D) Water-soluble extracts of A. fumigatus mycelium separated by SDS-
PAGE, transferred onto nitrocellulose membrane and stained with either the Galf-specific monoclonal antibody 
EB-A2 (left) or mannose-specific lectin Concanavalin A (ConA, right). 
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Figure 6 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 The morphology and growth of Aspergillus fumigatus ∆glfB is altered. A) Colony morphology of A. 
fumigatus wild type (wt) and the ∆glfB mutant after two days of growth on minimal agar at various 
temperatures. B) Absolute and relative growth rates obtained from colony diameter measurements (+/- Standard 
Error of the Mean, n = 3). 
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SUPPLEMENTAL DATA 
 
Suppl Figure 1 
 
Suppl Fig 1 UDP-Galf HPLC profile. 10 µl of a 2 mM UDP-Galf solution were loaded on a CarboPac PA-100 
column (Dionex) and eluted with a linear gradient of 75 to 500 mM KH2PO4 (dashed line, flow rate 1 ml/min) 
(36). UMP and UDP were identified from retention times of genuine species, and UDP-Galf retention time was 
derived from (36). Peak area comparison (assuming identical extinction coefficients) yielded a UMP content of 
about 6-7 % in the UDP-Galf preparation used in our study.  
 
 
Suppl Table 1 
Acc. No. Description in the RefSeq Database Locus Tag TMDs TC # TC Subfamily 
Possible 
Substrate 
XP_750355 nucleotide-sugar transporter AFUA_1G06050 8 2.A.7 No subfamily yet  
XP_752298 DUF6 domain protein AFUA_1G09310 9 2.A.7 No subfamily yet  
XP_756111 integral membrane protein AFUA_2G17760 9 2.A.7 No subfamily yet  
XP_754351 DUF250 domain membrane protein (GlfB) AFUA_3G12700 11 2.A.7 No subfamily yet UDP-Galf 
XP_750700 nucleotide-sugar transporter AFUA_6G08100 10 2.A.7 No subfamily yet  
XP_747139 solute transporter AFUA_8G00660 8 2.A.7 No subfamily yet  
XP_747138 integral membrane protein AFUA_8G00670 9 2.A.7 No subfamily yet  
XP_753855 DUF914 domain membrane protein AFUA_5G07810 10 2.A.7 No subfamily yet  
XP_747907 ER to Golgi transport protein (Sly41) AFUA_5G04360 8 2.A.7.9 
Triose-phosphate Transporter 
(TPT) Family  
XP_746924 UPD-GlcNAc transporter (Mnn2-2) AFUA_8G02830 9 2.A.7.10 
UDP-N-
Acetylglucosamine:UMP 
Antiporter (UAA) Family UDP-GlcNAc 
XP_750293 UDP-Glc/Gal ER nucleotide sugar transporter AFUA_1G05440 10 2.A.7.11 
UDP-Galactose:UMP 
Antiporter (UGA) Family 
UDP-Gal, 
PAPS 
XP_751184 UDP-galactose transporter AFUA_6G13070 7 2.A.7.12 
CMP-Sialate:CMP Antiporter 
(CSA) Family UDP-Gal 
XP_746997 nucleotide-sugar transporter AFUA_8G02090 5 2.A.7.12 
CMP-Sialate:CMP Antiporter 
(CSA) Family UDP-Gal 
XP_754058 Golgi GDP-mannose transporter AFUA_5G05740 10 2.A.7.13 
GDP-Mannose:GMP Antiporter 
(GMA) Family GDP-Man 
XP_752704 DUF6 domain protein AFUA_1G13340 10 2.A.7.24 
Thiamine Pyrophosphate 
Transporter (TPPT) Family 
Thiamine 
derivatives 
XP_753437 integral membrane protein AFUA_5G12140 9 2.A.7.24 
Thiamine Pyrophosphate 
Transporter (TPPT) Family 
Thiamine 
derivatives 
 
Suppl Table 1 Aspergillus fumigatus (Af293) nucleotide sugar transporter candidates. The number of 
transmembrane domains (TMDs) predicted by ConPredII (http://bioinfo.si.hirosaki-u.ac.jp/~ConPred2/) is 
given, together with family classification according to the TC system (http://www.tcdb.org) and putative 
substrates.
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Chapter 4 – General Discussion 
Standard therapy of invasive fungal infections comprises two classes of antifungals, amphotericin B 
and triazoles. The former has been the gold standard in the therapy of invasive fungal infections for 
decades despite limited efficacy, severe side effects and nephrotoxicity. First-generation triazoles 
(fluconazole, itraconazole) have been suffering from a limited activity spectrum and a multiple drug 
interactions. Newly-developed triazoles (voriconazole, posaconazole) have considerably improved 
efficacy and broad-spectrum activity and are now an established part of standard antifungal therapy 
and prophylaxis (Sable et al. 2008, Zonios and Bennett 2008).  
Yet for Invasive Aspergillosis the mortality remains unacceptably high (20-80 %), which is why 
much of current mycological research is devoted to the identification of new drug targets in its major 
causative agent, A. fumigatus. This has been difficult due to the opportunistic nature of A. fumigatus 
pathogenicity and the resulting absence of specific virulence traits. Moreover, the conservation of 
most of the vital cellular pathways between fungi and humans impedes their use as drug targets. As a 
consequence, only few targets have been identified that are both fungus-specific and truly essential 
for survival or virulence: 1) The biosynthesis of siderophores that scavenge and store iron (Schrettl et 
al. 2004, Hissen et al. 2005); 2) The biosynthesis of essential amino acids (Liebmann et al. 2004); 3) 
The biosynthesis of the cofactor folate (Sandhu et al. 1976, Brown et al. 2000); and 4) the 
biosynthesis of cell wall β1,3-glucan (Firon et al. 2002, Mouyna et al. 2004). 
The latter example demonstrates the suitability of cell wall polysaccharide biosynthesis as a source of 
new drug targets. The major part of the cell wall consists of β1,3-glucan and perturbation of its 
biosynthesis is likely to have consequences for proper cell wall function, such as protection against 
mechanical and osmotic stress. Notably, inhibitors of fungal β1,3-glucan synthesis form the third and 
newest class of antifungals, the echinocandins (caspofungin, micafungin, anidulafungin) which show 
good efficacy against Candida spp. and Aspergillus spp. (Denning 2003).  
Little is known on the importance of the other major cell wall polysaccharides, chitin and 
galactomannan, for A. fumigatus. Chitin is required for the yeast S. cerevisiae to withstand osmotic 
stress (Schmidt 2004), however the efficacy of chitin inhibitors (nikkomycins, polyoxins) is hampered 
by their low penetration of fungal cell walls (Munro and Gow 2001). Nevertheless, nikkomycin Z 
shows synergistic effects with echinocandins against A. fumigatus in vitro and in experimental murine 
infection (Ganesan et al. 2004, Clemons and Stevens 2006).  
Studies on the importance of galactomannan had not been possible because no enzyme involved in its 
biosynthesis was known until the identification of UDP-galactopyranose mutase (UGM) which 
represents the first step in the galactofuranose biosynthesis pathway (Bakker et al. 2005a). One goal 
of this study was thus to evaluate the drug target potential of UDP-Galf biosynthesis in A. fumigatus 
by means of a UGM deficient mutant. Moreover, the identification of a UDP-Galf transporter 
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presented in this study showed that galactomannan biosynthesis and all other galactofuranosylation 
reactions depend on this UDP-Galf transporter and thus are situated in the secretory pathway, most 
likely the Golgi apparatus. This is an unexpected finding since the other cell wall polysaccharides are 
synthesized at the plasma membrane.     
 
4.1  Importance of galactofuranosylation for growth and 
morphology of A. fumigatus  
Single deletion of either UDP-galactopyranose mutase (UGM), encoded by or the newly identified 
UDP-Galf transporter resulted in a complete loss of galactofuranosylated glycans. This comprised not 
only N- and O-glycans and glycoinositolphosphoceramides (GIPCs) but also cell wall galactomannan 
whose biosynthesis had not been studied to date. The requirement of UGM for galactofuranosylation 
was not surprising as this enzyme is known to be the only route to UDP-Galf biosynthesis in bacteria 
and protozoa (Stevenson et al. 1994, Pan et al. 2001, Kleczka et al. 2007).  
The severity of the phenotype induced by Galf deficiency varies between different organisms. In 
mycobacteria, deletion of the UGM gene is lethal (Pan et al. 2001). This is a peculiarity as these 
organisms possess a unique cell wall structure composed of outer cell wall mycolic acids that are 
linked to the inner cell wall peptidoglycan through Galf containing arabinogalactan. Without Galf, the 
mycolic acids would detach from the peptidoglycan which is likely to cause the lethal effect. However 
this cell wall structure is not found in other organisms and thus the importance of Galf for 
mycobacteria cannot be generalized. In E. coli, UGM deficiency causes loss of LPS O-antigen, and 
thus virulence, but results in perfectly viable mutants (Stevenson et al. 1994). This resembles the 
findings in L. major, the only eukaryote in which the UGM gene has been deleted so far. This mutant 
is characterized by the loss of its most abundant cell surface polysaccharide, LPG, resulting in 
attenuated virulence but no detectable growth Galf defect (Kleczka et al. 2007).  
In all these mutants the Galf deficiency phenotype is caused by molecules that contain internal Galf 
residues (arabinogalactan/mycolic acids, LPS, LPG) and thus become severely truncated in the case 
of Galf absence. This is totally different in A. fumigatus and other filamentous fungi, in which Galf or 
short chains of Galf are found exclusively in terminal positions.  
However, the loss of Galf leads still to a considerably thinner cell wall, altered culture morphology, 
increased drug susceptibility, reduced sporulation and thermotolerance and a growth defect. Similar 
effects were observed recently in UGM deficient mutants of A. niger and A. nidulans and might thus 
be generalized to other filamentous fungi (Damveld et al. 2008, El Ganiny et al. 2008). These findings 
resemble the phenotype of a galactosylation deficient mutant of Schizosaccharomyces pombe. In this 
yeast the loss of galactose on the cell wall galactomannan, induced by deletion of the Golgi UDP-
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galactose transporter, results in a thinner cell wall, a growth defect and increased drug susceptibility 
similar to the defects seen in the A. fumigatus ∆glfA and ∆glfB mutants (Tanaka et al. 2001).  
 
More than 100 fungal genomes have been sequenced to date and in these species the occurrence of 
Galf can be predicted from the presence of glfA and glfB homologs. Remarkably, within the 
ascomycota all pezizomycotina (i.e. the mycelial ascomycetes) seem to produce Galf. This correlates 
perfectly with chemical analyses on the cell wall composition of members of this subphylum. In 
contrast, no ascomycetous yeast (subphyla saccharomycotina and taphrinomycotina) is predicted or 
has been shown to contain Galf. It might thus be possible that there is a link between the occurrence 
of Galf and the mycelial lifestyle of the pezizomycotina. Little is known about fungi of other phyla, 
however some basidiomycetous yeasts, such as Cryptococcus neoformans, also contain Galf.    
 
4.2 The Aspergillus fumigatus UDP-Galf transporter  
From studies in yeast and other eukaryotes it is known that processing of the Man8GlcNAc2 N-glycan 
precursor, O-glycosylation and GIPC biosynthesis occur in the Golgi (Dean 1999, Goto 2007, Lisman 
et al. 2004), thus this is the likely site of galactofuranosylation of N- and O-glycans and GIPCs. From 
studies in Leishmania it is known that the galactofuranosyl donor UDP-Galf is synthesized in the 
cytosol (Kleczka et al. 2007), therefore it has to be transported into the Golgi lumen to be available 
for galactofuranosyltransferases. However, no UDP-Galf specific nucleotide sugar transporter (NST) 
has been described to date nor had any NST been studied in filamentous fungi. As the sequence 
conservation between NST genes is generally low, candidate genes might be identified by database 
mining but it is not possible to predict substrate specificity. 
Sixteen NST candidate genes were identified in the A. fumigatus genome by homology to known NST 
genes from other species. Intriguingly, one of them was found next to the UGM encoding gene glfA. 
BLAST comparison of this gene, named glfB, to characterized NST genes did not allow classification 
into one of the six established NST families (Saier et al. 2009) but showed relationship to three 
recently identified plant UDP-Gal transporters (Bakker et al. 2005b, Rollwitz et al. 2006). To 
determine the substrate specificity of GlfB, the uptake of radiolabeled nucleotide sugars into Golgi 
vesicles of a yeast strain overexpressing glfB was measured. It was not possible though to test UDP-
Galf directly as it was available only in a non-radioactive form. No transport activity was found for 
the UDP-sugars UDP-Gal, UDP-GlcNAc, UDP-GalNAc or UDP-GlcA. Many NSTs work 
preferentially as antiporters, translocating a nucleotide sugar in exchange for the corresponding 
nucleoside monophosphate, e.g. UDP-Gal for UMP or GDP-Man for GMP (Muraoka et al. 2007, 
Hong et al. 2000). Thus the NST binding site shows affinity for both, the nucleoside monophosphate 
and the nucleotide sugar. In a competition experiment it was shown that UDP-Galf, but not UDP-Gal 
  General Discussion 
  
  58 
or UDP-GlcNAc, could inhibit GlfB-mediated UMP transport. This supported the assumption that 
GlfB was an NST with specificity for UDP-Galf.   
To test this hypothesis, a glfB gene deletion mutant was created in A. fumigatus and analyzed for 
defects in galactofuranosylation. Remarkably, the ∆glfB mutant was completely devoid of Galf as 
seen for galactomannan and GIPCs by reactivity towards Galf-specific antibodies and electrophoretic 
N-glycan analysis. These findings were exactly mimicking the molecular phenotype of the ∆glfA 
mutant and as expected, the ∆glfB mutant displayed likewise a growth defect, reduced sporulation and 
decreased thermotolerance. Thus, the ∆glfB mutant showed a total loss of galactofuranosylation and 
combined with the in vitro findings on GlfB transport activity it could be concluded that GlfB encodes 
a UDP-Galf transporter. Moreover, the total loss of Galf indicates that GlfB is the sole UDP-Galf 
transporter in A. fumigatus.  
 
Remarkably, the UDP-Galf transporter deficiency also affects cell wall galactomannan biosynthesis 
which suggests that galactofuranosylation of galactomannan occurs likewise in the secretory pathway, 
most likely the Golgi. In contrast, the homopolymeric cell wall polysaccharides β1,3/1,6-glucan, α1,3-
glucan, and chitin are synthesized in multi-enzyme complexes at the plasma membrane (Latgé 2007). 
In this context the existence of a GPI-linked galactomannan is of particular interest as it suggests a 
galactomannan biosynthesis model (fig. 4-1). In this model, the GPI-galactomannan would be 
synthesized in the Golgi and subsequently transported to the plasma membrane. There GPI-
galactomannan could serve as a donor of ‘galactomannan units’ for a yet unknown extracellular 
‘galactomannosyltransglycosidase’ which would transfer galactomannan from its GPI-anchor onto the 
cell wall β1,3/1,6-glucan. Two transglycosidases with a comparable activity are known in A. 
fumigatus. The extracellular glucanosyltransferases Gel1 and Gel2 cleave β1,3-glucan chains and 
transfer the resulting oligosaccharide on another β1,3-glucan chain (Hartland et al. 1996, Mouyna et 
al. 2005). Furthermore, in yeasts some cell wall proteins are covalently linked to the cell wall β1,3-
glucan through a remnant of a GPI-anchor (Klis et al. 2007). This suggests the existence of GPI-
specific transglycosidases in the yeast cell wall and it has been speculated that similar mechanisms 
exist in Aspergilli (Damveld et al. 2005). This model would be consistent with an exclusively Golgi-
localized UDP-Galf transporter, however this has to be confirmed in additional experiments. 
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Figure 4-1 Proposed model of galactomannan biosynthesis. Galactomannan units are synthesized on a GPI 
anchor by subsequent action of mannosyltransferases (1) and galactofuranosyltransferases (2) in the Golgi. GPI-
galactomannan is then transported to the plasma membrane (3) where galactomannan is finally transferred from 
its GPI anchor to the β1,3-glucan (4).  
 
The described model of galactomannan biosynthesis allows furthermore to predict that deletion of the 
Golgi GDP-Man transporter should lead to a stronger glycosylation defect than the one observed in 
the ∆glfA and ∆glfB mutants. Not only galactomannan biosynthesis would be completely abrogated, 
but also O-glycosylation, GIPC biosynthesis, and the putative N-glycan Golgi mannosylation (fig. 3-
6). The A. fumigatus genome indeed contains a single GDP-mannose transporter candidate gene, and 
its gene product was characterized in vitro as a GDP-Man transporter in the course of this study (data 
not shown). However, attempts to produce a gene deletion mutant in A. fumigatus have failed so far. 
The repeated difficulties in isolating a GDP-Man transporter deficient mutant might indicate that the 
GDP-Man transporter is essential for A. fumigatus. In several yeast species, the GDP-Man transporter 
has turned out to be essential as demonstrated by gene deletion mutants in Saccharomyces cerevisiae, 
Candida albicans and Candida glabrata (Dean et al. 1997, Nishikawa et al. 2002b, Nishikawa et al. 
2002a). The importance of the GDP-mannose transporter for yeasts likely results from the combined 
loss of hypermannosylated N-glycans (fig. 3-4) and elongated O-glycans. However the 
hypermannosylation of N-glycans is a yeast-specific process that has not been observed in 
filamentous fungi and protein O-glycosylation seems dispensable in A. fumigatus (Zhou et al. 2007, 
Wagener et al. 2008). GIPC biosynthesis is not essential for S. cerevisiae but required for full 
virulence of C. albicans (Beeler et al. 1997, Mille et al. 2004) and current analyses carried out in 
collaboration with F. Ebel (LMU Munich) indicate that GIPCs are dispensable for A. fumigatus, too.    
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4.3 The galactofuranose biosynthesis pathway as drug target 
The absence of Galf in the ∆glfA mutant resulted in attenuated virulence in a murine model of 
Invasive Aspergillosis. A growth defect comparable to the one seen under culture conditions was 
observed in the mouse lung and provides a reasonable explanation for the delayed onset of infection. 
Additional experiments carried out to elucidate whether an altered immune response was elicited 
towards the ∆glfA mutant did not show any difference compared to wild type (data not shown). 
Comparison with other cell wall glycosylation mutants shows that the impact of Galf absence can be 
compared with impaired (not absent) β1,3-glucan or chitin biosynthesis. The double knockout of two 
of the seven chitin synthase genes (ChsG and ChsE) or the deletion of cell wall β1,3-
glucanosyltransferase Gel2 each lead to a growth defect and reduced virulence (Mellado et al. 1996, 
Mouyna et al. 2005). However other glycosylation defects, such as loss of cell wall α1,3-glucans or 
partial loss of O-glycans, do not affect virulence or even growth of the mutant strains (Beauvais et al. 
2005a, Zhuo et al. 2007). Often the deletion of a gene involved in cell wall biosynthesis of 
A. fumigatus yields unexpectedly viable mutants. In some cases this can be explained by multi-copy 
genes that functionally compensate for each other, most impressively demonstrated by the seven 
different chitin synthase genes (Latgé 2007). Besides, fungi possess a ‘cell wall integrity pathway’ 
that senses various kinds of cell wall stress and responds with the upregulation of numerous cell wall 
biosynthesis genes, among them synthases for chitin, β1,3-glucan and α1,3-glucan (Lagorce et al. 
2003). Thus, cell wall defects caused by the absence of a specific cell wall polysaccharide can often 
be compensated by an increased production of other cell wall components. Beta-1,3-glucan 
biosynthesis however, is strictly essential for A. fumigatus as demonstrated by RNAi-mediated 
downregulation of the β1,3-glucan synthase Fks1 (Mouyna et al. 2004). 
To overcome the compensatory mechanism provided by the cell wall integrity pathway it has been 
attempted to target the biosynthesis of different cell wall polysaccharides simultaneously. Such 
synergistic effect is demonstrated by the chitin synthase inhibitor nikkomycin Z. When administered 
alone it poorly inhibits growth of A. fumigatus, both in vitro and in vivo (Clemons and Stevens 2006, 
Ganesan et al. 2004). However it shows synergistic effects with the echinocandins caspofungin and 
micafungin (Ganesan et al. 2004, Stevens 2000). Similarly, the ∆glfA mutant was four to eight times 
more sensitive to nikkomycin Z. Moreover, the susceptibility to caspofungin and amphotericin B was 
increased twofold and even eightfold to voriconazole. Remarkably, the MIC of voriconazole was 
decreased to 0.04 µg/ml in the ∆glfA mutant which is 100 times less than the MIC of the ‘gold 
standard’ amphotericin B in the wild type. These findings encourage the evaluation of UGM 
inhibitors as adjunct drugs to second-generation triazole antifungals like voriconazole or 
posaconazole.       
UDP-Galf biosynthesis has been recognized as attractive drug target in mycobacteria since 
arabinogalactan is essential for mycobacterial growth (Pan et al. 2001). A range of 2-aminothiazoles 
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have been designed as inhibitors of mycobacterial UGM and some of them prevent mycobacterial 
growth as effectively as currently used antimycobacterial drugs (Dykhuizen et al. 2008). These 
inhibitors are also effective against Klebsiella pneumoniae UGM. However, the sequence divergence 
between bacterial UGMs and A. fumigatus UGM is high and the three-dimensional structure of 
A. fumigatus UGM is not yet known, so inhibitors against bacterial UGMs have a high chance to be 
inefficient against A. fumigatus UGM (Beverley et al. 2005). In collaboration with L. Kiessling 
(Wisconsin University), a panel of 2-aminothiazoles have been identified that inhibit both bacterial 
and A. fumigatus UGM with good efficacy (T. Gruber, L.L. Kiessling, unpublished results). 
Preliminary experiments with A. fumigatus cultures showed that these inhibitors recapitulated the 
∆glfA phenotype on minimal medium agar plates at 50 µM (data not shown). These findings 
demonstrate the cell wall/plasma membrane permeability of these compounds which is an essential 
property of a drug and suggests that the 2-aminothiazole backbone is a good starting point for the 
development of a new antifungal. The soon-awaited solution of the three-dimensional structure of 
A. fumigatus UGM will greatly aid the optimization of a 2-aminothiazole drug lead and holds out the 
prospect of an efficient adjunct drug against A. fumigatus. 
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4.4 Supplemental figure 
 
 
 
Suppl Figure Occurrence of Galf in the fungal kingdom. Species containing adjacent glfA and glfB homologs 
(red); a glfA homolog in unknown relation to glfB (faint red); glfA and glfB in moderate (yellow) or greater 
(brown) chromosomal distance; or no glfA and glfB homologs (black).  
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Abbreviations 
 
AIDS Acquired Immunodeficiency Syndrome 
 
DC Dendritic Cell 
Dol Dolichol 
 
ER Endoplasmic Reticulum 
ERK Extracellular signal Regulated Kinase 
 
FAD Flavin Adenine Dinucleotide 
Fuc Fucose 
 
Gal Galactopyranose 
Galf Galactofuranose 
GalNAc N-Acetyl-galactosamine 
GIPC Glycosylinositolphosphoceramide 
GIPL Glycoinositolphospholipids 
Glc Glucose 
GlcN Glucosamine 
GlcNAc N-Acetyl-glucosamine 
GPI Glycophosphatidylinositol 
 
HSCT Hematopoietic Stem Cell Transplantation  
 
IA Invasive Aspergillosis 
IPC Inositolphosphoceramide 
 
LPG Lipophosphoglycan 
LPS Lipopolysaccharide 
 
Man Mannose 
MAPK Mitogen-associated Protein Kinase 
 
NADPH Nicotinamide Adenine Dinucleotide Phosphate  
Neu5Ac N-Acetylneuraminic acid 
NF-κB Nuclear Factor κB 
NST Nucleotide Sugar Transporter 
 
P Phosphate 
 
UDP Uridine-5’-diphosphate 
UGM UDP-galactopyranose mutase 
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